US6509514B1 - Chimeric animal model susceptible to human hepatitis C virus infection - Google Patents
Chimeric animal model susceptible to human hepatitis C virus infection Download PDFInfo
- Publication number
- US6509514B1 US6509514B1 US09/528,120 US52812000A US6509514B1 US 6509514 B1 US6509514 B1 US 6509514B1 US 52812000 A US52812000 A US 52812000A US 6509514 B1 US6509514 B1 US 6509514B1
- Authority
- US
- United States
- Prior art keywords
- host
- human
- mouse
- chimeric
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 109
- 238000010171 animal model Methods 0.000 title abstract description 28
- 208000010710 hepatitis C virus infection Diseases 0.000 title 1
- 241000282414 Homo sapiens Species 0.000 claims abstract description 129
- 208000015181 infectious disease Diseases 0.000 claims abstract description 82
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- 210000004185 liver Anatomy 0.000 claims abstract description 50
- 244000052769 pathogen Species 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 36
- 108700019146 Transgenes Proteins 0.000 claims abstract description 34
- 230000003494 hepatotrophic effect Effects 0.000 claims abstract description 25
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 24
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 23
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 19
- 210000003494 hepatocyte Anatomy 0.000 claims description 77
- 210000002966 serum Anatomy 0.000 claims description 48
- 230000001717 pathogenic effect Effects 0.000 claims description 39
- 230000003612 virological effect Effects 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 21
- 238000011830 transgenic mouse model Methods 0.000 claims description 21
- 210000005229 liver cell Anatomy 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 230000010076 replication Effects 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 238000011081 inoculation Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 101000930477 Mus musculus Albumin Proteins 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 126
- 230000009261 transgenic effect Effects 0.000 abstract description 21
- 230000014509 gene expression Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- -1 e.g. Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 49
- 241000700721 Hepatitis B virus Species 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 102000008100 Human Serum Albumin Human genes 0.000 description 24
- 108091006905 Human Serum Albumin Proteins 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 238000002054 transplantation Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 18
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 241001529936 Murinae Species 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000010240 RT-PCR analysis Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 229960005356 urokinase Drugs 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 101100188554 Arabidopsis thaliana OCT5 gene Proteins 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283923 Marmota monax Species 0.000 description 3
- 208000012266 Needlestick injury Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 230000010558 Gene Alterations Effects 0.000 description 2
- 241000941423 Grom virus Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000288754 Scandentia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 2
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 101100230981 Mus musculus Hgf gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 101100230982 Rattus norvegicus Hgf gene Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
Definitions
- the present invention relates generally to the field of infectious disease, particularly to models for viral pathogens.
- HBV hepatitis B virus
- HCV human hepatitis C virus
- HBV and HCV also differ in their infectivity. HCV is less infectious than an equivalent dose of HBV, as evidenced by the differences in acquisition rates in hospital personnel after needlestick injuries. HBV infections occur in 2-40% of HBV-contaminated needlestick events, while HCV infections occur in only 3-10% of HCV-contaminated needlestick events. These observations suggest that HCV is about three to four times less infectious than HBV (Shapiro Surgical Clin North Amer. 75(6):1047-56 (1995)).
- HBV and HCV differ greatly in their requirements for replication as well as in the viral load during infection.
- HBV is capable of replicating in less differentiated systems (e.g., HepG2 cells, Sells et al. Proc. Natl. Acad. Sci. USA 84:1005 (1987)).
- HCV replication may depend upon the presence of nontransformed hepatocytes (see, e.g., Ito et al. J. Gen. Virol. 77:1043 (1995)).
- the viral titers of patients infected with HCV are generally lower than those of HBV-infected patients.
- Patients infected with HBV have levels ranging from 10 5 to 10 9 particles per mL, compared to 10 2 to 10 7 particles per mL in HCV infections. These differences in viral titer may be due at least in part to the relative clearance rates of viral particles.
- the number of viral copies per cell is also very low in HCV infection (e.g., generally less than 20 copies per cell (Dhillon et al. Histopathology 26:297-309 (1995)). This combination of low viral titers and low number of viral copies per cell means that a significant number of human hepatocytes must be infected and producing virus for the infection to even be detected within serum.
- HCV has been reported to infect primary cultures of human hepatocytes; however, the cells do not support the production of progeny virions (Fournier et al. J Gen Virol 79(Pt 10):2367-74 (1998)). The development of a satisfactory in vivo model is required in order to provide a more clinically relevant means for assaying candidate therapeutic agents.
- the extremely narrow host range of HBV and HCV has made it very difficult to develop animal models.
- Current animal models of HBV and HCV either do not involve the normal course of infection, require the use of previously infected human liver cells, or both (see, e.g., U.S. Pat. Nos.
- the most desirable animal model would be a chimeric animal model that allowed for infection of human liver cells through the normal route of infection, preferably a mouse model susceptible to viral infection through intravenous inoculation and that could support chronic infection.
- a mouse model susceptible to viral infection through intravenous inoculation and that could support chronic infection.
- mice having chimeric livers with human hepatocytes susceptible to HBV or HCV infection, and sustaining viral replication and virion production at clinically relevant, sustainable levels has proven no simple matter.
- the field of xenogeneic liver transplantation has moved very slowly and met with many obstacles.
- the first advance was the development of a mouse transgenic for an albumin-urokinase-type plasminogen activator construct (Alb-uPA) (Heckel et al.
- the Alb-uPA transgene includes a murine urokinase gene under the control of the albumin promoter, resulting in the targeting of urokinase production to the liver and producing a profoundly hypofibrinogenemic state and accelerated hepatocyte death. Later work with this transgenic animal demonstrated that individual hepatocytes that spontaneously deleted the transgene acquired a significant survival and replicative advantage, resulting in repopulation of the liver with these nontransgenic cells Sandgren et al., (1991), supra).
- Hepatocyte growth factor is the most potent stimulus of hepatocyte regeneration in vivo; in comparing sequence data, mouse HGF was shown to have 98.5% amino acid sequence homology with rat HGF, and only 90.9% with human HGF (Liu et al. Biochim et Biophys Acta 1216;:299-303 (1993)). There were no guarantees of success.
- the present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV).
- the model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver.
- the invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
- An advantage of the invention is that the animal model provides the first instance of an animal that is susceptible to infection by HCV via the normal route of infection, and further that can become chronically, consistently, and stably infected at viral titers that can be equated to viral titers in HCV-infected humans.
- Still another advantage of the invention is that production of the animal model does not require obtaining or handling HBV-infected or HCV-infected cells.
- the invention avoids the need to obtain hepatocytes from HBV- or HCV-infected human donors or to culture and infect human hepatocytes in vitro.
- the animal model does not require special maintenance or handling other than that normal associated with virally-infected, immunocompromised animals.
- FIG. 1 is a Western blot of human albumin (HA) production in recipient serum samples over time in animals carrying or not carrying the Alb-uPA transgene
- FIG. 6 is a graph illustrating production of albumin from human hepatocyte grafts (1 ⁇ 10 6 cells) in four recipients carrying the Alb-uPA transgene.
- FIG. 7 is a Western blot of HA production in an Alb-uPA-positive recipient post-transplant showing sustained signal intensity.
- HA human albumin standard (50 ng); Con-nontransplanted mouse serum control.
- liver cell includes a plurality of such liver cells
- non-human animal includes reference to one or more non-human animals and equivalents thereof known to those skilled in the art, and so forth.
- Chimeric as used herein (e.g., “chimeric animal” or “chimeric liver”) is meant to describe an organ or animal comprising xenogeneic tissues or cells. Of particular interest is a chimeric animal, wherein the animal is chimeric due to the presence of human hepatocytes engrafted in the animal's liver.
- immunocompromised is meant that the animal can not mount a complete or significant immune response against the xenogeneic tissue or cells, e.g., any immune response of the host animal is such that it is ineffective in rejection of the transplanted cells.
- transgene is used herein to describe genetic material which has been or is about to be artificially inserted into the genome of a mammalian, particularly a mammalian cell of a living animal.
- transgenic animal is meant a non-human animal, usually a mammal, having a non-endogenous (i.e., heterologous) nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells).
- heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal according to methods well known in the art.
- a “transgene” is meant to refer to such heterologous nucleic acid, e.g., heterologous nucleic acid in the form of an expression construct (e.g., for the production of a “knock-in” transgenic animal) or a heterologous nucleic acid that upon insertion within or adjacent a target gene results in a decrease in target gene expression (e.g., for production of a “knock-out” transgenic animal).
- a “knock-out” of a gene means an alteration in the sequence of the gene that results in a decrease of function of the target gene, preferably such that target gene expression is undetectable or insignificant.
- Transgenic knock-out animals can be comprise a heterozygous knock-out of a target gene, or a homozygous knock-out of a target gene.
- “Knock-outs” as used herein also include conditional knock-outs, where alteration of the target gene can occur upon, for example, exposure of the animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site (e.g., Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.
- a “knock-in” of a target gene means an alteration in a host cell genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of a target gene, e.g., by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene.
- “Knock-in” transgenics can comprise a heterozygous knock-in of the target gene or a homozygous knock-in of a target gene.
- “Knock-ins” also encompass conditional knock-ins.
- operably linked is meant that a DNA sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).
- operatively inserted is meant that a nucleotide sequence of interest is positioned adjacent a nucleotide sequence that directs transcription and translation of the introduced nucleotide sequence of interest.
- therapeutic agent refers to any molecule, e.g., protein or small molecule, pharmaceutical compound, antibody, antisense molecule, ribozyme, and the like, useful in the treatment of a disease or condition, e.g., a liver condition, including, but not necessarily limited to infection by HBV and/or HCV.
- therapeutic agents of the invention include molecules that inhibit, ameliorate, or relieve symptoms associated with viral infection, and in particular HBV and/or HCV.
- unit dosage form refers to physically discrete units suitable as unitary dosages for subjects (e.g., animals, usually humans), each unit containing a predetermined quantity of agent(s) in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle.
- the specifications for the novel unit dosage forms of the present invention will depend on a variety of factors including, but not necessarily limited to, the particular agent employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
- treatment generally mean obtaining a desired pharmacologic and/or physiologic effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
- Treatment covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or (c) relieving the disease, i.e., causing regression of the disease.
- the present invention is based on the development of a murine animal model for hepatitis C virus (HCV).
- the murine animal model generally involves transplantation of human hepatocytes into the liver of a transgenic mouse at an appropriate stage of the host's development, preferably shortly after birth of the host.
- success in the development of the model is due at least in part to the following: 1) use of a host having an immunodeficient background, thus avoiding immune destruction of introduced xenogenic (human) cells; 2) the use of a transgenic animal that contains a transgene for urokinase, which provides an ongoing potent stimulus to hepatocyte growth and cellular division; and, 3) introduction of viable human hepatocytes into the host animal at an appropriate time in the hepatocyte life cycle and at an early stage of the host animal's development to provide for long-term survival of either large numbers and/or a high percentage of human cells in the host.
- the present invention for the first time provides a non-primate host for use as a model of HCV infection that can be infected through the normal route of infection (e.g., by intravenous inoculation).
- This aspect of the invention is particularly important for use in the development of anti-viral agents.
- the animal model of the invention does not require the use of pre-infected human hepatocytes, thus avoiding the handling of infected tissue isolated from human donors or infecting the human hepatocytes in vitro prior to implantation.
- the invention features a chimeric animal as described above, as well as a method of producing a chimeric animal by transplanting human hepatocytes into the liver of an immunocompromised, urokinase transgene-bearing animal.
- the invention features methods of using the chimeric animal model described herein, including methods of identifying agents for treatment of infections by a hepatotrophic microbial pathogen.
- the host animal is generally a non-human, immunocompromised mammal having an increased production in the liver of urokinase-type plasminogen activator (uPA) and in which human hepatocytes can be engrafted and maintained.
- uPA urokinase-type plasminogen activator
- the host animal is of the genus Rodentia, preferably a mouse.
- the host animal is an immunocompromised mouse, preferably an immunocompromised mouse transgenic for urokinase-type plasminogen activator (uPA), more preferably an immunocompromised mouse comprising a transgene that provides for liver-specific production of uPA (e.g., an Alb-uPA transgene, see, e.g., Heckel et al Cell 62:447 (1990)).
- uPA urokinase-type plasminogen activator
- Mice suitable for use in the present invention can be produced from any of a variety of background strains including, but not necessarily limited to, the strains C.B-17, C3H, BALB/c, C57131/6, AKR, BA, B10, 129, etc.
- the host animal may be either male or female.
- the host animal is preferably immunocompromised.
- Immunocompromised mammalian hosts suitable for implantation and having the desired immune incapacity are available.
- immunocompromised animals can be generated from immunocompetent animals by, for example, administration of one or more compounds (e.g., cyclosporin) and other methods well known in the art.
- the immunocompromised host can not mount a complete immune response against the xenogeneic tissue or cells.
- immunocompromised animals that have one or more genetic defects that leads to significantly decreased numbers of or no detectable functional T cells, B cells, and natural killer (NK) cells relative to normal.
- mice that have a homozygous mutation at the scid locus (scid/scid).
- the scid mutation is associated with a deficiency in DNA-dependent protein kinase catalytic subunit and prevents VDJ recombination in immunoglobulin and T-cell receptor genes.
- Animals homozygous for the scid mutation lack functionally recombined immunoglobulin and T-cell receptor genes and thus are deficient in both T and B cell lineages.
- the scid/scid mutation is available or may be bred into a number of different genetic backgrounds, e.g., CB.17, ICR (outbred), C3H, BALB/c, C57B1/6, AKR, BA, B10, 129, etc.
- the invention can also take advantage of animals having the beige mutation (bg), which is associated with a natural killer (NK) cell deficiency.
- mice are produced having both the scid mutation and the bg beige mutation, resulting in an animal that does not mount an effective immune response to allogeneic or xenogeneic cells or tissues introduced to the organisms.
- mice genetically engineered to lack the recombinase function associated with RAG-1 and/or RAG-2 (e.g., commercially available TIMTM RAG-2 transgenic), to lack Class I and/or Class II MHC antigens (e.g., the commercially available C1D and C2D transgenic strains), or to lack expression of the Bcl-2 proto-oncogene.
- Other mice that may be useful as recipients are NOD scid/scid; SGB scid/scid, bh/bh; CB.17 scid/hr; NIH-3 bg/nu/xid and META nu/nu.
- Immunocompromised rats include HsdHan:RNU-rnu; HsdHan:RNU-rnu/+; HsdHan:NZNU-rnu; HsdHan:NZNU-rnu/+; LEW/HanHsd-rnu; LEW/HanHsd-rnu/+; WAG/HanHsd-rnu and WAG/HanHsd-rnu/+.
- the chimeric animal of the invention is also a “knock-in” transgenic for expression of urokinase-type plasminogen activator (uPA).
- the transgene is the Alb-uPA transgene, which comprises a murine albumin enhancer/promoter, the murine uPA gene coding region, an the 3′ untranslated and flanking sequences of the growth hormone gene (Heckel et al. Cell 62:447-56 (1990); Sandgren et al. Cell 66:245-56 (1991)).
- the host animal may be either heterozygous or homozygous for the urokinase-type plasminogen activator transgene; homozygous animals are strongly preferred as the success rate of HCV infection with such homozygous animals is greater than that with heterozygous animals.
- the Alb-uPA transgene results in a lethal insult to hepatocytes that carry it, and also results in a high local (intrahepatic) concentration of urokinase, which in turn processes hepatocyte growth factor to its active form within the liver.
- viable allogeneic or xenogeneic cells introduced at an appropriate time in the development of an Alb-uPA transgenic animal are stimulated to replicate in this environment. The donor cells thus grow to “replace” the endogenous hepatocytes that die as a result of the lethal insult of the transgene.
- the isolation procedure and handling and storage protocol serve to minimize warm ischemia following cessation of blood flow to the liver (e.g., generally less than about 20 min to 40 min, preferably less than about min to about 20 min) and to minimize cold ischemia that may result from storage (e.g., generally less than about 12 hr, usually less than about 1 hr to 2 hrs).
- the human tissue is normal, e.g., having no detectable pathogens, normal in morphology and histology, and essentially disease-free).
- the final suspension used for implantation generally comprises at least about 50-75% hepatocytes, usually at least about 80-99% hepatocytes.
- the timing of the introduction of the donor hepatocytes into the transgenic, immunocompromised host may be important to the production of a chimeric liver populated with a number of human hepatocytes sufficient to render the chimeric liver susceptible to infection by a hepatotrophic pathogen and to support replication of the pathogen. This may be particularly true where the hepatotrophic pathogen exhibits low infectivity and/or low replication rates (e.g., HCV). Where the animal is murine (e.g., a mouse), the host is ideally less than 10 days to 2 weeks in age, and optimally about 7 to 10 days old, or less than or about one week (i.e., less than or about 5 to 7 days old or younger), at the time of transplantation.
- timing of transplantation indicated herein is a compromise between excess technical mortality associated with very early transplantation (i.e., due to the small size of the animals) and the time for maximal replicative stimulus (e.g., the number of cell divisions in the recipient liver that occur before transplant may influence the success and extent of engraftment of the donor human cells). Furthermore, timing of transplantation is also important since the stimulus for liver cell repopulation provided by the transgene diminishes with time, and is generally depleted after the recipient is more than about 6 weeks old (Rhim et al. (1994) Science 263:1149-52)60%.
- the human hepatocytes can be transplanted using any suitable method known in the art.
- the human hepatocytes are injected intrasplenically, e.g., into the inferior splenic pole.
- Successful engraftment can be monitored by conventional methods, e.g., by examining the levels of human liver-specific proteins in the host serum, e.g., human serum albumin (HA).
- the chimeric host can be used for experimentation (e.g., for infection with a hepatotrophic pathogen, to screen candidate agents, etc.) when suitable.
- the animal is to be infected with a hepatotrophic agent of relative low infectivity and/or low replicative capacity
- the chimeric animal can be inoculated within about four to six weeks post-transplant, generally at about six weeks post-transplant, and may be as early as three weeks post-transplant.
- the animal host develops human chimerism within its liver such that the percentage of liver cells that are human liver cells are from at least about 20% to 50%, generally about 40% to 60% and may be up to 90% or more.
- the chimeric animal can be maintained with functional transplanted hepatocytes for at least several weeks, generally at least about 5 weeks, more usually at least about 12 weeks to 24 weeks, up to 8 months or more, and may be up to the lifespan of the host.
- Chimeric animals can be infected with a hepatotrophic pathogen (e.g., HBV or HCV), particularly a hepatotrophic pathogen having a host range limited to primates, particularly humans.
- a hepatotrophic pathogen e.g., HBV or HCV
- chronically infected chimeric hosts can be maintained for a period of weeks to months.
- the chimeric animal can become chronically infected with HCV (e.g., chronically infected) and maintain an active HCV infection for a period of at least about 5 weeks, generally at least about 14 weeks to about 20 weeks or more, and may be for the lifespan of the host.
- HCV chronically infected
- the viral load of the infected host can be established such that it is similar to the viral load of an infected human.
- the host animal can support infection at a level of from about 10 4 to about 10 6 viral particles/ml serum, generally from about 10 3 to about 10 7 viral particles/ml serum.
- the viral load of the infected host over time is substantially consistent, chronic, and stable, e.g., the number of viral particles that can be isolated from the infected, untreated host's serum does not radically fluctuate between sampling periods, e.g., an HCV-infected host of the invention that contains a high number of HCV viral particles per mL of serum at a first sampling time is positive for HCV infection at subsequent sampling times and generally has the same or similar high level of HCV particles per mL of serum.
- Once stable infection is established in the host generally within about 2 to 4 weeks post-infection.
- the viral load of the infected host does not fluctuate radically so as to allow assessment of the effect of a candidate antiviral agent, e.g., the viral titer is chronic and consistent.
- the chimeric animal of the invention can be used in a variety of other screening assays.
- any of a variety of candidate agents suspected of causing or contributing to hepatic disease, as well as the appropriate antagonists and blocking therapeutic agents can be screened by administration to the chimeric animal and assessing the effect of these agents upon function of the engrafted human cells.
- Function of the engrafted human liver cells can be assessed as described above (e.g., by assessing levels of human serum albumin in the host serum).
- the animal model of the invention can be used to identify candidate agents that, for example, inhibit or prevent infection by, replication of, or disease symptoms caused by a hepatotrophic pathogen (e.g., bacteria, virus, parasite, especially a hepatotrophic virus such as HBV or HCV).
- a hepatotrophic pathogen e.g., bacteria, virus, parasite, especially a hepatotrophic virus such as HBV or HCV.
- a hepatotrophic pathogen e.g., bacteria, virus, parasite, especially a hepatotrophic virus such as HBV or HCV.
- Candidate agents is meant to include synthetic, naturally occurring, or recombinantly produced molecules (e.g., small molecule; drugs; peptides; antibodies (including antigen-binding antibody fragments, e.g., to provide for passive immunity); endogenous factors present in eukaryotic or prokaryotic cells (e.g., polypeptides, plant extracts, and the like)); etc.).
- synthetic, naturally occurring, or recombinantly produced molecules e.g., small molecule; drugs; peptides; antibodies (including antigen-binding antibody fragments, e.g., to provide for passive immunity); endogenous factors present in eukaryotic or prokaryotic cells (e.g., polypeptides, plant extracts, and the like)); etc.
- screening assays for agents that have a low toxicity for human cells e.g., small molecule; drugs; peptides; antibodies (including antigen-binding antibody fragments, e.g., to provide
- Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons.
- Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.
- the candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
- Candidate agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
- Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
- the animal model of the invention is used to identify agents that ameliorate symptoms caused by HBV or HCV infection and/or to more directly affect a pathogenic mechanism of the infecting virus, e.g., inhibit viral infection, decrease viral replication, or otherwise disrupt the cycle of viral propagation.
- the candidate agent is administered to the animal model of the invention, and the effects of the candidate agent assessed relative to a control.
- the candidate agent can be administered to an HCV-infected animal of the invention, and the viral titer of the treated animal (e.g., as measured by RT-PCR of serum samples) compared to the viral titer of the animal prior to treatment and/or to a control, untreated HCV-infected animal.
- a detectable and significant decrease in viral titer of an infected animal following treatment with a candidate agent is indicative of antiviral activity of the agent.
- the candidate agent can be administered in any manner desired and/or appropriate for delivery of the agent in order to effect a desired result.
- the candidate agent can be administered by injection (e.g., by injection intravenously, intramuscularly, subcutaneously, or directly into the tissue in which the desired affect is to be achieved), orally, or by any other desirable means.
- the in vivo screen will involve a number of animals receiving varying amounts and concentrations of the candidate agent (from no agent to an amount of agent hat approaches an upper limit of the amount that can be delivered successfully to the animal), and may include delivery of the agent in different formulations and routes.
- the agents can be administered singly or can be combined in combinations of two or more, especially where administration of a combination of agents may result in a synergistic effect.
- the activity of the candidate agent can be assessed in a variety of ways.
- a hepatotrophic pathogen e.g., HBV, HCV, etc.
- the effect of the agent can be assessed by examining serum samples for the presence of the pathogen (e.g., titer, as in viral titer) or markers associated with the presence of the pathogen (e.g., a pathogen-specific protein or encoding nucleic acid, etc.)
- the pathogen e.g., titer, as in viral titer
- markers associated with the presence of the pathogen e.g., a pathogen-specific protein or encoding nucleic acid, etc.
- Qualitative and quantitative methods for detecting and assessing the presence and severity of viral infection are well known in the art.
- the activity of an agent against HBV infection can be assessed by examining serum samples and/or tissue sections for the presence of a viral antigen (e.g., HBV surface antigen (HBsAg), HBV core antigen (HbcAg), etc.).
- a viral antigen e.g., HBV surface antigen (HBsAg), HBV core antigen (HbcAg), etc.
- the activity of an agent against viral infection can be assessed by examining serum samples for the presence of viral nucleic acid (e.g., HCV RNA).
- HCV RNA can be detected using, for example, reverse transcriptase polymerase chain reaction (RT-PCR), competitive RT-PCR or branched-DNA (bDNA) assay, detection of negative-strand RNA (the replicative intermediate of HCV) by RT-PCR, or sequencing of viral RNA to detect mutation/shift in the viral genome (“quasispecies evolution”) with therapy.
- RT-PCR reverse transcriptase polymerase chain reaction
- bDNA branched-DNA
- detection of negative-strand RNA the replicative intermediate of HCV
- sequencing of viral RNA to detect mutation/shift in the viral genome (“quasispecies evolution”) with therapy.
- the host liver may be biopsied and in situ RT-PCR hybridization performed to demonstrate directly any qualitative or quantitative alterations in the amount of viral particles within tissue sections.
- the host can be euthanized and the liver examined histologically for signs of infection and/or toxicity caused by the agent.
- the compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment.
- the therapeutic agents may be administered in a variety of ways, orally, topically, parenterally e.g. subcutaneously, intraperitoneally, intravascularly, by inhalation, etc. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways.
- the concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt. %.
- compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like.
- Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds.
- Diluents known to the art include aqueous media, vegetable and animal oils and fats.
- Stabilizing agents, wetting and emulsifying Agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.
- the animal model of the invention can also be used to screen candidate vaccines for their ability to prevent or ameliorate infection by a hepatotrophic pathogen.
- a “vaccine” is an agent that, following administration, facilitates the host in mounting an immune response against the target pathogen.
- the humoral, cellular, or humoral/cellular immune response elicited can facilitate inhibition of infection by the pathogen against which the vaccine is developed.
- vaccines that elicit an immune response that inhibits infection by and/or intrahepatic replication of a hepatotrophic pathogen, e.g., a microbial, viral, or parasitic pathogen, particularly a viral pathogen, e.g., HBV and/or HCV.
- the immune system of the immunocompromised chimeric animal is reconstituted using, for example, stem cells of human origin to provide for a human immune system in the animal.
- Methods for isolating human immune cells and reconstitution of the immune system of an immunocompromised animal, e.g., a mouse with an human immune system are well known in the art (see, e.g., Nature 335:256-59; Proc. Natl. Acad. Sci. USA 93(25):14720-25).
- the human immune cells are obtained from the same donor as the human hepatocytes used in the production of the chimeric liver.
- the human immune cells are introduced into the host according to methods well known in the art, e.g., by intraperitoneal injection.
- the candidate vaccine is administered to the chimeric animal prior to inoculation with the hepatotrophic pathogen.
- the candidate vaccine is generally administered by providing a single bolus (e.g., intraperitoneal or intramuscular injection, topical administration, or oral administration), followed by one or more booster immunizations.
- the induction of an immune response can be assessed by examining B and T cell responses that are specific for the antigen according to methods well known in the art.
- the immunized animal is then challenged with the hepatotrophic pathogen; normally several immunized animals are challenged with increasing titers of the pathogen.
- Vaccine candidates that provide for a significant decrease in infection by the pathogen and/or a significant decrease in the severity of disease that results post-challenge are identified as viable vaccines.
- the chimeric animal of the invention can be infected, preferably chronically infected, with a hepatotrophic agent, and used as a source from which the agent can be isolated.
- This use of the chimeric animal of the invention is particularly useful where, for example, isolation of the pathogen requires biopsy from a human subject or is difficult to obtain in useful amounts; the pathogen cannot be readily cultured in vitro; culturing of the pathogen in vitro (e.g., growth in broth culture or in cultured cells) leads to changes in the pathogen that may affects its pathogenicity and/or clinical relevance; etc.
- the chimeric animal is inoculated with the isolated pathogen by an appropriate route (e.g., by intravenous, intramuscular, intraperitoneal, or oral administration), preferably by a route of infection that best correlates with the natural route of infection in human disease.
- an appropriate route e.g., by intravenous, intramuscular, intraperitoneal, or oral administration
- the pathogen is isolated from the infected chimeric animal by an appropriate method (e.g., isolation from a blood sample, from liver, etc.).
- the chimeric animal can also be used in the course of diagnosis of liver disease in a human.
- a sample suspected of containing the causative agent can be isolated from the patient (e.g., from the patient's serum or from a liver biopsy).
- the sample can be enriched for the suspected agent, fractionated, or otherwise processed to provide it in an administrable form, and administered to the chimeric animal.
- the chimeric animal can then be evaluated to assess the effect of administration of the sample upon the engrafted human hepatocytes.
- the effect upon the human hepatocytes can be accomplished by, for example, isolation and examination of serum samples from the chimeric animal, e.g., to assess function of the engrafted human hepatocytes, and/or to detect a pathogen in the animal's serum, e.g., to detect the presence of HCV or other microbial pathogen).
- the human hepatocytes can also be examined histologically to determine the effect of the patient sample.
- the invention can also be adapted to provide for diagnosis and rationale therapy designed on an individualized basis.
- human hepatocytes obtained by biopsy of a patient e.g., percutaneous needle biopsy
- This chimeric murine host can then be used to evaluate the hepatotrophic pathogen infecting the patient, assess the pathogen's susceptibility to therapeutic agents, and to assess the potential toxicity of the patient's hepatocytes to such therapy.
- the invention can be designed to facilitate tailoring of therapies most effective against an individual's specific hepatotrophic pathogen complement (e.g., against one or more infecting hepatotrophic pathogens).
- mice heterozygous for the transgene (strain TgN(AlblPlau)144Bri (The Jackson Laboratory)) were crossed with animals from a C.B-17/SCID-beige lineage (rain C.B-17/GbmsTac-scid-bgN7 (Taconic Farms), homozygous).
- SCID-beige trait was bred to homozygosity as confirmed by quantification of total serum IgG using a sandwich ELISA technique to detect mouse IgG according to methods well known in the art.
- the transgene was maintained in the heterozygous state as the homozygous trait is associated with a high perinatal mortality rate secondary to bleeding complications and liver failure (Heckel et al. Cell 62:447 (1990)). Animals were housed in virus/antigen-free conditions, and were cared for in accordance with the guidelines established by the Canadian Council on Animal Care (1993). All animal experiments describe Herein were performed with approval from the University of Alberta Animal Welfare Committee.
- Hepatocytes were filtered through 100 ⁇ m stainless steel mesh, purified by density-gradient centrifugation (Percoll, density 1.04 g/mL; Sigma) at 400 g for 5 minutes, and washed twice in ice-cold HBSS prior to suspension in Belzer-University of Wisconsin solution (DuPont) at 0° C. for short-term storage prior to transplantation. Cell counts and viability were confirmed by trypan blue exclusion prior to transplantation; final viability was routinely >80%.
- offspring (5-14 days old) were anesthetized with Halothane/O 2 , and a small left flank incision was made.
- 1 ⁇ 10 6 viable hepatocytes were injected into the inferior splenic pole with a 27 g butterfly injection set (Becton-Dickinson), and a single sterile titanium clip was placed across the injection site for hemostasis. The spleen was returned to the abdomen, and the flank incision was closed in two layers.
- albumin Since the production of albumin is an exclusive property of hepatocytes (Clement et al, Hepatology 4:373 (1984); Gunsalas et al. Nature Medicine 3:48 (1997)), detection of human albumin (HA) in serum samples by selective immunoprecipitation and Western blotting was employed as an indicator of graft cell function. Recipient mice were initially sampled by jugular venous puncture at four weeks post-transplant, and at weekly intervals thereafter. Aliquots of mouse serum (20 ⁇ l) were incubated with an anti-human albumin monoclonal antibody (Clone HSA-9; Sigma), and antigen-antibody complexes were precipitated with protein G-agarose (Boehringer-Mannheim).
- Imnunoprecipitates were heated for 5 minutes at 98° C. in SDS buffer containing 0.2 M dithiothreitol, separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose.
- Western blots were prepared in standard fashion (Coligan et al. Current Protocols in Immunology (Wiley, N.Y., 1997), vol. 2, chap. 8.10.7) using a second anti-human albumin monoclonal antibody (Clone HSA- 11; Sigma) conjugated to biotin as the primary.
- a streptavidin-HRP conjugate (Pierce) was employed as the secondary, and chemiluminescent reagents (Pierce) were used for signal detection.
- cryosections of recipient livers were obtained at various times after transplantation and immunostained with a monoclonal antibody specific for human MHC Class I. Segments of mouse liver were placed in OCT compound and snap-frozen in liquid nitrogen. Cryosections were fixed in acetone and embedded in paraffin; immunohistochemistry was performed as previously described (Korbutt et al. J Clin Invest 97:2119 (1996)).
- a murine monoclonal antibody specific for human MHC Class I was expressed and purified from the BB7.7 cell line (ATCC), conjugated to biotin and used as the primary antibody.
- An avidin/peroxidase complex (Vector; Burlingame, Calif.) was used as a secondary, with peroxide/diaminobenzidine employed as the chromagen.
- FIGS. 2-5 The results of these experiments are shown in FIGS. 2-5.
- animals carrying the transgene clusters of cells staining positive for human MHC (darkly stained cells) were scattered uniformly throughout the host liver at two weeks post-transplant, comprising an estimated 2-3% of all hepatocytes (FIGS. 2 (control) and 3 (transplanted)).
- the percentage of positive-staining cells had increased, covering from 20 to 60% of the total surface area of individual sections (FIG. 4 ).
- the interface between human and mouse cells was distinct, with cords of human cells extending into the surrounding murine parenchyma (FIG. 5 ).
- Individual human cells maintained a normal appearance and developed sinusoidal architecture, although portal triad structures were notably absent from the regenerating nodules.
- This example demonstrates successful transplantation of the immunocompromised, Alb-uPA mice with human hepatocytes.
- hepatocytes available for use at the time of this experiment were obtained from a patient who was a chronic carrier of hepatitis B virus.
- the patient exhibited both a positive serum HBsAg levels and negative serum HBV DNA, indicating a chronic carrier state without active viral replication (Davis, South. Med. J. 90:866 (1997)).
- graft function began to slowly decline, with extinction of the HA signal at 10, 15 or 16 weeks.
- the fourth transgenic animal (mouse no. 6) showed maximal HA production at all measured timepoints (FIGS. 6 and 7 ), indicating stable engraftment of human hepatocytes.
- Sustained graft function repeatedly occurred in approximately 25% of animals carrying the transgene.
- the proliferative signal for the transplanted hepatocytes is likely dependent on overall expression of the transgene, and is reduced as host-derived hepatocytes spontaneously delete the transgene.
- HBsAg hepatitis B surface antigen
- Negative human and mouse serum controls range from 0.04-0.05 absorbance units; positive human controls range from 0.30-0.40 absorbance units.
- HA Alb-uPA Expression HBsAg Level Post-Transplant* Mouse Genotype Pattern 6 wk 8 wk 10 wk 12 wk 16 wk 1 ⁇ Absent ND 0.04 0.04 0.04 ND 2 ⁇ Absent 0.04 0.03 ND 0.02 ND 3 + Transient 0.04 0.03 0.08 0.05 ND 4 + Transient 0.12 0.04 0.07 0.04 ND 5 + Transient 0.04 0.03 ND 0.04 ND 6 + Persistent 0.13 0.13 ⁇ 3.18 ⁇ 3.78 ⁇ 3.44 ⁇ Key: HA — human albumin; ND — not done; *HBsAg levels expressed as absorbance units. ⁇ Samples positive for HBV DNA by PCR analysis.
- mice had undetectable HBsAg levels and the three transgenic animals with transient graft function showed only sporadic minimal increases during weeks 6-12.
- the transgenic mouse with the pattern of sustained graft function demonstrated clearly elevated levels at all time points measured, with an abrupt increase after 8 weeks to persist well within the range of HBsAg levels in actively infected human controls. The abrupt increase was suggestive of restoration of active viral replication.
- mice Seven littermates were transplanted at 7 days of age with human hepatocytes isolated from a patient serologically-negative for both HCV and HBV infection. After confirming initial graft function in 5/7 animals at 6 weeks post-transplant, all mice were inoculated intravenously with 0.25 mL of human serum obtained from an unrelated HCV-positive donor. The HCV-positive status of the human serum donor was confirmed positive for HCV RNA by PCR, with viral titers of 1 ⁇ 10 7 copies per ml serum. Thus, each mouse was inoculated with approximately 2.5 ⁇ 10 6 viral particles.
- mice Serum samples taken from all seven mice at 11, 12 and 13 weeks post-transplant (5, 6 and 7 weeks post-infection) were analyzed for the presence of HCV RNA by RT-PCR analysis using the Cobras Amplicon system (Roche Diagnostics), according to the manufacturer's instructions. Two nontransplanted mice served as mock-infected controls.
- the samples from the HCV-infection host can be diluted with known noninfected serum (e.g., about two to four fold dilution), to provide a sample volume adequate for use in an automated machine, and provide signal strengths in the assays indistinguishable from random human samples.
- known noninfected serum e.g., about two to four fold dilution
- Long-term replication of HCV in the model of the invention allows for the use of the model in the testing of drugs over extended periods of time, which period may be necessary for adequate drug development.
- the effect of administration of interferon- ⁇ , an anti-HCV therapy is generally only detectable in humans after about 12 weeks of therapy.
- the present invention provides a model that avoids this problem.
- this is the first report of a non-primate animal model that is susceptible to HCV infection by a normal route of infection.
- the model is clinically relevant (e.g., can be infected by a normal route of infection, and supports persistent HCV infection similar to that observed in humans), is cost-effective and relatively easy to produce, and will allow investigators to directly explore strategies for inhibiting viral replication in vivo.
- Example 3 The above experiments of Example 3 were repeated in 18 mice.
- the mouse name (used as an internal reference), gender, number of copies of the Alb-uPA transgene, identify of parents and date of birth (DOB) for each animal is provided in Table 2.
- Mice were transplanted with either fresh (fresh) or fresh frozen (cryo) human hepatocytes at ages ranging from 7 days to 13 days.
- the HA signal was detected by Western blot at 5 weeks to identify those animals that were successfully engrafted.
- the animals were subsequently infected with HCV as described above.
- RT-PCR was used to detect the presence of HCV in samples form each animal as described above. The results are summarized in Table 2.
- RT-PCR was performed quantitatively to determine the number of virions per ml of serum, the data is provided.
- Txplt Quantitative Mouse Sex uPA Parents DOB Txplt # cells Age 5 w Alb HCV RT-PCR titres Rpt wstrn A6MRA* M Homo 30-Mar 6-Apr 1 M f 7 d.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
Description
The present invention relates generally to the field of infectious disease, particularly to models for viral pathogens.
Despite their similar sounding names, human hepatitis B virus (HBV) and human hepatitis C virus (HCV) are completely different viruses. Both viruses are referred to as “hepatitis” viruses primarily because HBV and HCV infect and replicate in the liver. Aside from this, HBV and HCV are no more alike than are HIV and EBV, which each affect the immune system. In fact, HBV and HCV are so different that they are not even member of the same phylogenetic family. HBV is a member of the hepadnavirus family while HCV is a member of the flavivirus family.
HBV and HCV also differ in their infectivity. HCV is less infectious than an equivalent dose of HBV, as evidenced by the differences in acquisition rates in hospital personnel after needlestick injuries. HBV infections occur in 2-40% of HBV-contaminated needlestick events, while HCV infections occur in only 3-10% of HCV-contaminated needlestick events. These observations suggest that HCV is about three to four times less infectious than HBV (Shapiro Surgical Clin North Amer. 75(6):1047-56 (1995)).
HBV and HCV differ greatly in their requirements for replication as well as in the viral load during infection. HBV is capable of replicating in less differentiated systems (e.g., HepG2 cells, Sells et al. Proc. Natl. Acad. Sci. USA 84:1005 (1987)). In contrast, HCV replication may depend upon the presence of nontransformed hepatocytes (see, e.g., Ito et al. J. Gen. Virol. 77:1043 (1995)). The viral titers of patients infected with HCV are generally lower than those of HBV-infected patients. Patients infected with HBV have levels ranging from 105 to 109 particles per mL, compared to 102 to 107 particles per mL in HCV infections. These differences in viral titer may be due at least in part to the relative clearance rates of viral particles. In addition, the number of viral copies per cell is also very low in HCV infection (e.g., generally less than 20 copies per cell (Dhillon et al. Histopathology 26:297-309 (1995)). This combination of low viral titers and low number of viral copies per cell means that a significant number of human hepatocytes must be infected and producing virus for the infection to even be detected within serum.
The limited host range of human HBV and human HCV has proved problematic in the development of in vitro and in vivo models of infection. Humans and chimpanzees are the only animals susceptible to human HBV infection; human, chimpanzees, and tree shrews are susceptible for infection with human HCV (Xie et al. Virology 244:513-20 (1998), reporting transient infection of tree shrews with HCV). Human HBV will infect isolated human liver cells in culture (see, e.g., Sureau Arch. Virol. 8:3-14 (1993); Lampertico et al. Hepatology 13;422-6 (1991)). HCV has been reported to infect primary cultures of human hepatocytes; however, the cells do not support the production of progeny virions (Fournier et al. J Gen Virol 79(Pt 10):2367-74 (1998)). The development of a satisfactory in vivo model is required in order to provide a more clinically relevant means for assaying candidate therapeutic agents. The extremely narrow host range of HBV and HCV has made it very difficult to develop animal models. Current animal models of HBV and HCV either do not involve the normal course of infection, require the use of previously infected human liver cells, or both (see, e.g., U.S. Pat. Nos. 5,709,843; 5,652,373; 5,804,160; 5,849,288; 5,858,328; and 5,866,757; describing a chimeric mouse model for HBV infection by transplanting HBV-infected human liver cells under the mouse kidney capsule; WO 99/16307 and Galun et al. J. Infect. Dis. 172:25-30 (1995), describing transplantation of HCV-infected human hepatocytes into liver of immunodeficient mice; Bronowicki et al. Hepatology 28:211-8 (1998), describing intraperitoneal injection of HCV-infected hematopoietic cells into SCID mice; and Lerta et al. Hepatology 28(4Pt2):498A (1998), describing mice transgenic for the HCV genome). Infection by human HBV is fairly well mimicked by infection of woodchucks with woodchuck hepatitis virus (WHV) and by infection of Peking ducks with duck hepatitis virus (DHV). WHV-infected woodchucks and DHV-infected ducks have been successfully used to identify drugs effective against human HBV infection of humans. However, no analogous animal model of infection has been identified for human HCV.
In the absence of a practical non-human host, the most desirable animal model would be a chimeric animal model that allowed for infection of human liver cells through the normal route of infection, preferably a mouse model susceptible to viral infection through intravenous inoculation and that could support chronic infection. Unfortunately, the development of mice having chimeric livers with human hepatocytes susceptible to HBV or HCV infection, and sustaining viral replication and virion production at clinically relevant, sustainable levels has proven no simple matter. The field of xenogeneic liver transplantation has moved very slowly and met with many obstacles. The first advance was the development of a mouse transgenic for an albumin-urokinase-type plasminogen activator construct (Alb-uPA) (Heckel et al. Cell 62:447-56 (1990); Sandgren et al. Cell 66:245-56 (1991)). The Alb-uPA transgene includes a murine urokinase gene under the control of the albumin promoter, resulting in the targeting of urokinase production to the liver and producing a profoundly hypofibrinogenemic state and accelerated hepatocyte death. Later work with this transgenic animal demonstrated that individual hepatocytes that spontaneously deleted the transgene acquired a significant survival and replicative advantage, resulting in repopulation of the liver with these nontransgenic cells Sandgren et al., (1991), supra). The Alb-uPA transgenic mouse has proved amenable to transplantation with liver cells from non-transgenic mice (Rhim et al. Science 263:1149-52 (1994)). The Alb-uPA transgenic mouse was also successfully used to produce mice having chimeric livers with rat hepatocytes (Rhim et al. Proc. Natl. Acad. Sci. USA 92:4942-6 (1995)) or woodchuck hepatocytes (Petersen et al. Proc. Natl. Acad. Sci. USA 95:310-5 (1998). However, these developments were still a long step away from the development of an animal model susceptible to HBV infection or—even more challenging—susceptible to HCV infection. Production of mouse having a xenogeneic transplant from another member of the Rodentia family is not nearly as difficult or unexpected as production of a mouse having a xenogeneic transplant from an animal of a different family, e.g., a human. Hepatocyte growth factor (HGF) is the most potent stimulus of hepatocyte regeneration in vivo; in comparing sequence data, mouse HGF was shown to have 98.5% amino acid sequence homology with rat HGF, and only 90.9% with human HGF (Liu et al. Biochim et Biophys Acta 1216;:299-303 (1993)). There were no guarantees of success.
There is a need in the field for a human-mouse liver chimera susceptible to chronic infection by HBV or with HCV and with viral production at clinically relevant levels. The present invention addresses this problem.
The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
A primary object of the invention is to provide a non-human animal model that is susceptible to infection by human HCV via the normal route of infection.
An advantage of the invention is that the animal model provides the first instance of an animal that is susceptible to infection by HCV via the normal route of infection, and further that can become chronically, consistently, and stably infected at viral titers that can be equated to viral titers in HCV-infected humans.
Still another advantage of the invention is that production of the animal model does not require obtaining or handling HBV-infected or HCV-infected cells. Thus the invention avoids the need to obtain hepatocytes from HBV- or HCV-infected human donors or to culture and infect human hepatocytes in vitro. Furthermore, the animal model does not require special maintenance or handling other than that normal associated with virally-infected, immunocompromised animals.
These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the animal model and methods of its use as more fully described below.
FIG. 1 is a Western blot of human albumin (HA) production in recipient serum samples over time in animals carrying or not carrying the Alb-uPA transgene
FIGS. 2 and 3 represent negative (nontransplanted mouse liver; FIG. 2) and positive (human liver; FIG. 3) controls of immunohistochemical staining of paraffin-embedded liver cryosections with an anti-human MHC Class I monoclonal antibody. Bar=250 μm
FIG. 4 illustrates a low power magnification of recipient mouse liver sectioned at four weeks post-transplant, showing engraftment of human cells with transgenic liver parenchyma. Bar=1.25 mm.
FIG. 5 provides a higher magnification of the section of FIG. 4, showing a distinct border between human and murine tissue. Bar=250 μm.
FIG. 6 is a graph illustrating production of albumin from human hepatocyte grafts (1×106 cells) in four recipients carrying the Alb-uPA transgene.
FIG. 7 is a Western blot of HA production in an Alb-uPA-positive recipient post-transplant showing sustained signal intensity. HA—human albumin standard (50 ng); Con-nontransplanted mouse serum control.
Before the present invention is described, it is to be understood that this invention is not limited to particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a liver cell” includes a plurality of such liver cells and reference to “the non-human animal” includes reference to one or more non-human animals and equivalents thereof known to those skilled in the art, and so forth.
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Definitions
“Chimeric” as used herein (e.g., “chimeric animal” or “chimeric liver”) is meant to describe an organ or animal comprising xenogeneic tissues or cells. Of particular interest is a chimeric animal, wherein the animal is chimeric due to the presence of human hepatocytes engrafted in the animal's liver.
By “immunocompromised” is meant that the animal can not mount a complete or significant immune response against the xenogeneic tissue or cells, e.g., any immune response of the host animal is such that it is ineffective in rejection of the transplanted cells.
The term “transgene” is used herein to describe genetic material which has been or is about to be artificially inserted into the genome of a mammalian, particularly a mammalian cell of a living animal.
By “transgenic animal” is meant a non-human animal, usually a mammal, having a non-endogenous (i.e., heterologous) nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal according to methods well known in the art. A “transgene” is meant to refer to such heterologous nucleic acid, e.g., heterologous nucleic acid in the form of an expression construct (e.g., for the production of a “knock-in” transgenic animal) or a heterologous nucleic acid that upon insertion within or adjacent a target gene results in a decrease in target gene expression (e.g., for production of a “knock-out” transgenic animal).
A “knock-out” of a gene means an alteration in the sequence of the gene that results in a decrease of function of the target gene, preferably such that target gene expression is undetectable or insignificant. Transgenic knock-out animals can be comprise a heterozygous knock-out of a target gene, or a homozygous knock-out of a target gene. “Knock-outs” as used herein also include conditional knock-outs, where alteration of the target gene can occur upon, for example, exposure of the animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site (e.g., Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.
A “knock-in” of a target gene means an alteration in a host cell genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of a target gene, e.g., by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene. “Knock-in” transgenics can comprise a heterozygous knock-in of the target gene or a homozygous knock-in of a target gene. “Knock-ins” also encompass conditional knock-ins.
By “operably linked” is meant that a DNA sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).
By “operatively inserted” is meant that a nucleotide sequence of interest is positioned adjacent a nucleotide sequence that directs transcription and translation of the introduced nucleotide sequence of interest.
The term “therapeutic agent” as used herein refers to any molecule, e.g., protein or small molecule, pharmaceutical compound, antibody, antisense molecule, ribozyme, and the like, useful in the treatment of a disease or condition, e.g., a liver condition, including, but not necessarily limited to infection by HBV and/or HCV. For example, therapeutic agents of the invention include molecules that inhibit, ameliorate, or relieve symptoms associated with viral infection, and in particular HBV and/or HCV.
The term “unit dosage form” as used herein refers to physically discrete units suitable as unitary dosages for subjects (e.g., animals, usually humans), each unit containing a predetermined quantity of agent(s) in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the novel unit dosage forms of the present invention will depend on a variety of factors including, but not necessarily limited to, the particular agent employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.
The terms “treatment”, “treating” and the like are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. “Treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or (c) relieving the disease, i.e., causing regression of the disease.
Overview
The present invention is based on the development of a murine animal model for hepatitis C virus (HCV). The murine animal model generally involves transplantation of human hepatocytes into the liver of a transgenic mouse at an appropriate stage of the host's development, preferably shortly after birth of the host. Without being held to theory, success in the development of the model is due at least in part to the following: 1) use of a host having an immunodeficient background, thus avoiding immune destruction of introduced xenogenic (human) cells; 2) the use of a transgenic animal that contains a transgene for urokinase, which provides an ongoing potent stimulus to hepatocyte growth and cellular division; and, 3) introduction of viable human hepatocytes into the host animal at an appropriate time in the hepatocyte life cycle and at an early stage of the host animal's development to provide for long-term survival of either large numbers and/or a high percentage of human cells in the host.
To the best of the inventors' knowledge, the present invention for the first time provides a non-primate host for use as a model of HCV infection that can be infected through the normal route of infection (e.g., by intravenous inoculation). This aspect of the invention is particularly important for use in the development of anti-viral agents. Furthermore, the animal model of the invention does not require the use of pre-infected human hepatocytes, thus avoiding the handling of infected tissue isolated from human donors or infecting the human hepatocytes in vitro prior to implantation.
Accordingly the invention features a chimeric animal as described above, as well as a method of producing a chimeric animal by transplanting human hepatocytes into the liver of an immunocompromised, urokinase transgene-bearing animal. In addition the invention features methods of using the chimeric animal model described herein, including methods of identifying agents for treatment of infections by a hepatotrophic microbial pathogen.
The invention will now be described in more detail.
Host Animals
The host animal is generally a non-human, immunocompromised mammal having an increased production in the liver of urokinase-type plasminogen activator (uPA) and in which human hepatocytes can be engrafted and maintained. In one embodiment, the host animal is of the genus Rodentia, preferably a mouse. In a preferred embodiment, the host animal is an immunocompromised mouse, preferably an immunocompromised mouse transgenic for urokinase-type plasminogen activator (uPA), more preferably an immunocompromised mouse comprising a transgene that provides for liver-specific production of uPA (e.g., an Alb-uPA transgene, see, e.g., Heckel et al Cell 62:447 (1990)). Mice suitable for use in the present invention can be produced from any of a variety of background strains including, but not necessarily limited to, the strains C.B-17, C3H, BALB/c, C57131/6, AKR, BA, B10, 129, etc. The host animal may be either male or female.
Immunocompromised Background
As noted above, the host animal is preferably immunocompromised. Immunocompromised mammalian hosts suitable for implantation and having the desired immune incapacity are available. Alternatively, though less preferred, immunocompromised animals can be generated from immunocompetent animals by, for example, administration of one or more compounds (e.g., cyclosporin) and other methods well known in the art. In general, the immunocompromised host can not mount a complete immune response against the xenogeneic tissue or cells. Of particular interest are animals that are immunocompromised due to a genetic defect that results in an inability to undergo germline DNA rearrangement at the loci encoding immunoglobulins and T-cell antigen receptors. Also of interest are immunocompromised animals that have one or more genetic defects that leads to significantly decreased numbers of or no detectable functional T cells, B cells, and natural killer (NK) cells relative to normal.
Of particular interest are mice that have a homozygous mutation at the scid locus (scid/scid). The scid mutation is associated with a deficiency in DNA-dependent protein kinase catalytic subunit and prevents VDJ recombination in immunoglobulin and T-cell receptor genes. Animals homozygous for the scid mutation lack functionally recombined immunoglobulin and T-cell receptor genes and thus are deficient in both T and B cell lineages. The scid/scid mutation is available or may be bred into a number of different genetic backgrounds, e.g., CB.17, ICR (outbred), C3H, BALB/c, C57B1/6, AKR, BA, B10, 129, etc. The invention can also take advantage of animals having the beige mutation (bg), which is associated with a natural killer (NK) cell deficiency. In one embodiment, mice are produced having both the scid mutation and the bg beige mutation, resulting in an animal that does not mount an effective immune response to allogeneic or xenogeneic cells or tissues introduced to the organisms.
Other exemplary immunocompromised host that are presently available include transgenic mice genetically engineered to lack the recombinase function associated with RAG-1 and/or RAG-2 (e.g., commercially available TIM™ RAG-2 transgenic), to lack Class I and/or Class II MHC antigens (e.g., the commercially available C1D and C2D transgenic strains), or to lack expression of the Bcl-2 proto-oncogene. Other mice that may be useful as recipients are NOD scid/scid; SGB scid/scid, bh/bh; CB.17 scid/hr; NIH-3 bg/nu/xid and META nu/nu. Transgenic mice, rats and pigs are available which lack functional B cells and T cells due to a homozygous disruption in the CD3F-gene. Immunocompromised rats include HsdHan:RNU-rnu; HsdHan:RNU-rnu/+; HsdHan:NZNU-rnu; HsdHan:NZNU-rnu/+; LEW/HanHsd-rnu; LEW/HanHsd-rnu/+; WAG/HanHsd-rnu and WAG/HanHsd-rnu/+.
Transgenic Expression of Urokinase
As discussed above, the chimeric animal of the invention is also a “knock-in” transgenic for expression of urokinase-type plasminogen activator (uPA). In one embodiment, the transgene is the Alb-uPA transgene, which comprises a murine albumin enhancer/promoter, the murine uPA gene coding region, an the 3′ untranslated and flanking sequences of the growth hormone gene (Heckel et al. Cell 62:447-56 (1990); Sandgren et al. Cell 66:245-56 (1991)). While the host animal may be either heterozygous or homozygous for the urokinase-type plasminogen activator transgene; homozygous animals are strongly preferred as the success rate of HCV infection with such homozygous animals is greater than that with heterozygous animals. The Alb-uPA transgene results in a lethal insult to hepatocytes that carry it, and also results in a high local (intrahepatic) concentration of urokinase, which in turn processes hepatocyte growth factor to its active form within the liver. Without being held to theory, viable allogeneic or xenogeneic cells introduced at an appropriate time in the development of an Alb-uPA transgenic animal are stimulated to replicate in this environment. The donor cells thus grow to “replace” the endogenous hepatocytes that die as a result of the lethal insult of the transgene.
Isolation of Human Hepatocytes
Human hepatocytes for transplantation into the host animals are isolated from human liver tissue by any convenient method known in the art. In general, the human hepatocytes may be fresh tissue (e.g., obtained within hours of death), or freshly frozen tissue (e.g., fresh tissue frozen and maintained at or below about 0° C.). Ideally, the cells used are recently isolated (i.e., within 2 to 4 hours) from freshly obtained human liver tissue. Human hepatocytes that are placed in a defined cryopreservation media may be stored for long periods of time (e.g., in liquid nitrogen) and thawed as required, thus permitting the development of banks of stored hepatocytes. In general, it is usually important that the isolation procedure and handling and storage protocol serve to minimize warm ischemia following cessation of blood flow to the liver (e.g., generally less than about 20 min to 40 min, preferably less than about min to about 20 min) and to minimize cold ischemia that may result from storage (e.g., generally less than about 12 hr, usually less than about 1 hr to 2 hrs). In one embodiment, the human tissue is normal, e.g., having no detectable pathogens, normal in morphology and histology, and essentially disease-free).
The liver tissue can be dissociated mechanically or enzymatically to provide a suspension of single cells, or fragments of intact human hepatic tissue may be used. In a preferred embodiment, the hepatocytes are isolated from donor tissue by routine collagenase perfusion (Ryan et al. Meth. Cell Biol. 13:29 (1976)) followed by low-speed centrifugation. Hepatocytes can then be purified by filtering through a stainless steel mesh (e.g., 100 μm), followed by density-gradient centrifugation. Alternatively, other methods for enriching for hepatocytes can be used, e.g., fluorescence activated cell sorting, panning, magnetic bead separation, elutriation within a centrifugal field, etc. The final suspension used for implantation generally comprises at least about 50-75% hepatocytes, usually at least about 80-99% hepatocytes.
Transplantation of Human Hepatocytes into Hosts
The timing of the introduction of the donor hepatocytes into the transgenic, immunocompromised host may be important to the production of a chimeric liver populated with a number of human hepatocytes sufficient to render the chimeric liver susceptible to infection by a hepatotrophic pathogen and to support replication of the pathogen. This may be particularly true where the hepatotrophic pathogen exhibits low infectivity and/or low replication rates (e.g., HCV). Where the animal is murine (e.g., a mouse), the host is ideally less than 10 days to 2 weeks in age, and optimally about 7 to 10 days old, or less than or about one week (i.e., less than or about 5 to 7 days old or younger), at the time of transplantation. Without being held to theory, the timing of transplantation indicated herein is a compromise between excess technical mortality associated with very early transplantation (i.e., due to the small size of the animals) and the time for maximal replicative stimulus (e.g., the number of cell divisions in the recipient liver that occur before transplant may influence the success and extent of engraftment of the donor human cells). Furthermore, timing of transplantation is also important since the stimulus for liver cell repopulation provided by the transgene diminishes with time, and is generally depleted after the recipient is more than about 6 weeks old (Rhim et al. (1994) Science 263:1149-52)60%.
The human hepatocytes can be transplanted using any suitable method known in the art. Preferably, the human hepatocytes are injected intrasplenically, e.g., into the inferior splenic pole.
Successful engraftment can be monitored by conventional methods, e.g., by examining the levels of human liver-specific proteins in the host serum, e.g., human serum albumin (HA). The chimeric host can be used for experimentation (e.g., for infection with a hepatotrophic pathogen, to screen candidate agents, etc.) when suitable. Where the animal is to be infected with a hepatotrophic agent of relative low infectivity and/or low replicative capacity, the chimeric animal can be inoculated within about four to six weeks post-transplant, generally at about six weeks post-transplant, and may be as early as three weeks post-transplant.
In general, the animal host develops human chimerism within its liver such that the percentage of liver cells that are human liver cells are from at least about 20% to 50%, generally about 40% to 60% and may be up to 90% or more.
The chimeric animal can be maintained with functional transplanted hepatocytes for at least several weeks, generally at least about 5 weeks, more usually at least about 12 weeks to 24 weeks, up to 8 months or more, and may be up to the lifespan of the host. Chimeric animals can be infected with a hepatotrophic pathogen (e.g., HBV or HCV), particularly a hepatotrophic pathogen having a host range limited to primates, particularly humans. Depending upon the nature of the pathogen, chronically infected chimeric hosts can be maintained for a period of weeks to months. For example, where the hepatotrophic pathogen is HCV, the chimeric animal can become chronically infected with HCV (e.g., chronically infected) and maintain an active HCV infection for a period of at least about 5 weeks, generally at least about 14 weeks to about 20 weeks or more, and may be for the lifespan of the host.
The viral load of the infected host can be established such that it is similar to the viral load of an infected human. For example, where the pathogen is HCV, the host animal can support infection at a level of from about 104 to about 106 viral particles/ml serum, generally from about 103 to about 107 viral particles/ml serum.
The viral load of the infected host over time is substantially consistent, chronic, and stable, e.g., the number of viral particles that can be isolated from the infected, untreated host's serum does not radically fluctuate between sampling periods, e.g., an HCV-infected host of the invention that contains a high number of HCV viral particles per mL of serum at a first sampling time is positive for HCV infection at subsequent sampling times and generally has the same or similar high level of HCV particles per mL of serum. Once stable infection is established in the host, generally within about 2 to 4 weeks post-infection. In general, the viral load of the infected host does not fluctuate radically so as to allow assessment of the effect of a candidate antiviral agent, e.g., the viral titer is chronic and consistent.
Screening Assays
The chimeric animal of the invention can be used in a variety of other screening assays. For example, any of a variety of candidate agents suspected of causing or contributing to hepatic disease, as well as the appropriate antagonists and blocking therapeutic agents, can be screened by administration to the chimeric animal and assessing the effect of these agents upon function of the engrafted human cells. Function of the engrafted human liver cells can be assessed as described above (e.g., by assessing levels of human serum albumin in the host serum).
In one embodiment of particular interest, the animal model of the invention can be used to identify candidate agents that, for example, inhibit or prevent infection by, replication of, or disease symptoms caused by a hepatotrophic pathogen (e.g., bacteria, virus, parasite, especially a hepatotrophic virus such as HBV or HCV). Although the examples provided herein generally involve the use of chimeric murine hosts with a single hepatotrophic pathogen, the invention can also be used to identify a single candidate agent or a cocktail of candidate agents having activity against infection by two or more hepatotrophic agents.
“Candidate agents” is meant to include synthetic, naturally occurring, or recombinantly produced molecules (e.g., small molecule; drugs; peptides; antibodies (including antigen-binding antibody fragments, e.g., to provide for passive immunity); endogenous factors present in eukaryotic or prokaryotic cells (e.g., polypeptides, plant extracts, and the like)); etc.). Of particular interest are screening assays for agents that have a low toxicity for human cells.
Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
Screening of Candidate Anti-HBV or Anti-HCV Agents
In one embodiment, the animal model of the invention is used to identify agents that ameliorate symptoms caused by HBV or HCV infection and/or to more directly affect a pathogenic mechanism of the infecting virus, e.g., inhibit viral infection, decrease viral replication, or otherwise disrupt the cycle of viral propagation. In general, the candidate agent is administered to the animal model of the invention, and the effects of the candidate agent assessed relative to a control. For example, the candidate agent can be administered to an HCV-infected animal of the invention, and the viral titer of the treated animal (e.g., as measured by RT-PCR of serum samples) compared to the viral titer of the animal prior to treatment and/or to a control, untreated HCV-infected animal. In general, a detectable and significant decrease in viral titer of an infected animal following treatment with a candidate agent is indicative of antiviral activity of the agent.
The candidate agent can be administered in any manner desired and/or appropriate for delivery of the agent in order to effect a desired result. For example, the candidate agent can be administered by injection (e.g., by injection intravenously, intramuscularly, subcutaneously, or directly into the tissue in which the desired affect is to be achieved), orally, or by any other desirable means. Normally, the in vivo screen will involve a number of animals receiving varying amounts and concentrations of the candidate agent (from no agent to an amount of agent hat approaches an upper limit of the amount that can be delivered successfully to the animal), and may include delivery of the agent in different formulations and routes. The agents can be administered singly or can be combined in combinations of two or more, especially where administration of a combination of agents may result in a synergistic effect.
The activity of the candidate agent can be assessed in a variety of ways. For example, where the host animal is infected with a hepatotrophic pathogen (e.g., HBV, HCV, etc.), the effect of the agent can be assessed by examining serum samples for the presence of the pathogen (e.g., titer, as in viral titer) or markers associated with the presence of the pathogen (e.g., a pathogen-specific protein or encoding nucleic acid, etc.) Qualitative and quantitative methods for detecting and assessing the presence and severity of viral infection are well known in the art. In one embodiment, the activity of an agent against HBV infection can be assessed by examining serum samples and/or tissue sections for the presence of a viral antigen (e.g., HBV surface antigen (HBsAg), HBV core antigen (HbcAg), etc.). In another embodiment, the activity of an agent against viral infection can be assessed by examining serum samples for the presence of viral nucleic acid (e.g., HCV RNA). For example, HCV RNA can be detected using, for example, reverse transcriptase polymerase chain reaction (RT-PCR), competitive RT-PCR or branched-DNA (bDNA) assay, detection of negative-strand RNA (the replicative intermediate of HCV) by RT-PCR, or sequencing of viral RNA to detect mutation/shift in the viral genome (“quasispecies evolution”) with therapy. Alternatively or in addition, the host liver may be biopsied and in situ RT-PCR hybridization performed to demonstrate directly any qualitative or quantitative alterations in the amount of viral particles within tissue sections. Alternatively or in addition, the host can be euthanized and the liver examined histologically for signs of infection and/or toxicity caused by the agent.
Identified Agents
The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment. The therapeutic agents may be administered in a variety of ways, orally, topically, parenterally e.g. subcutaneously, intraperitoneally, intravascularly, by inhalation, etc. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt. %.
The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying Agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.
Vaccine Development
With some modifications, the animal model of the invention can also be used to screen candidate vaccines for their ability to prevent or ameliorate infection by a hepatotrophic pathogen. In general, a “vaccine” is an agent that, following administration, facilitates the host in mounting an immune response against the target pathogen. The humoral, cellular, or humoral/cellular immune response elicited can facilitate inhibition of infection by the pathogen against which the vaccine is developed. Of particular interest in the present invention are vaccines that elicit an immune response that inhibits infection by and/or intrahepatic replication of a hepatotrophic pathogen, e.g., a microbial, viral, or parasitic pathogen, particularly a viral pathogen, e.g., HBV and/or HCV.
In this embodiment of the invention, the immune system of the immunocompromised chimeric animal is reconstituted using, for example, stem cells of human origin to provide for a human immune system in the animal. Methods for isolating human immune cells and reconstitution of the immune system of an immunocompromised animal, e.g., a mouse with an human immune system are well known in the art (see, e.g., Nature 335:256-59; Proc. Natl. Acad. Sci. USA 93(25):14720-25). In one embodiment, the human immune cells are obtained from the same donor as the human hepatocytes used in the production of the chimeric liver. In one embodiment, the human immune cells are introduced into the host according to methods well known in the art, e.g., by intraperitoneal injection.
Screening for an effective vaccine is similar to screening methods described above. In short, the candidate vaccine is administered to the chimeric animal prior to inoculation with the hepatotrophic pathogen. The candidate vaccine is generally administered by providing a single bolus (e.g., intraperitoneal or intramuscular injection, topical administration, or oral administration), followed by one or more booster immunizations. The induction of an immune response can be assessed by examining B and T cell responses that are specific for the antigen according to methods well known in the art. The immunized animal is then challenged with the hepatotrophic pathogen; normally several immunized animals are challenged with increasing titers of the pathogen. The animals are then observed for development of infection, and the severity of infection assessed (e.g., by assessing the titer of the pathogen present, examining human hepatocyte function parameters as described above, etc.). Vaccine candidates that provide for a significant decrease in infection by the pathogen and/or a significant decrease in the severity of disease that results post-challenge are identified as viable vaccines.
Other Uses
Uses of the chimeric animal of the invention that are variations upon or in addition to those described above will be readily apparent to the ordinarily skilled artisan upon reading of the present specification. For example, the chimeric animal can be infected, preferably chronically infected, with a hepatotrophic agent, and used as a source from which the agent can be isolated. This use of the chimeric animal of the invention is particularly useful where, for example, isolation of the pathogen requires biopsy from a human subject or is difficult to obtain in useful amounts; the pathogen cannot be readily cultured in vitro; culturing of the pathogen in vitro (e.g., growth in broth culture or in cultured cells) leads to changes in the pathogen that may affects its pathogenicity and/or clinical relevance; etc. In general, the chimeric animal is inoculated with the isolated pathogen by an appropriate route (e.g., by intravenous, intramuscular, intraperitoneal, or oral administration), preferably by a route of infection that best correlates with the natural route of infection in human disease. After the pathogen establishes infection of the human hepatocytes, and after a sufficient amount of time has passed to allow replication of the pathogen, the pathogen is isolated from the infected chimeric animal by an appropriate method (e.g., isolation from a blood sample, from liver, etc.).
The chimeric animal can also be used in the course of diagnosis of liver disease in a human. For example, where the patient suffers from a liver disease of unknown origin or where diagnosis without culturing of the pathogen is not definitive, a sample suspected of containing the causative agent can be isolated from the patient (e.g., from the patient's serum or from a liver biopsy). The sample can be enriched for the suspected agent, fractionated, or otherwise processed to provide it in an administrable form, and administered to the chimeric animal. The chimeric animal can then be evaluated to assess the effect of administration of the sample upon the engrafted human hepatocytes. The effect upon the human hepatocytes can be accomplished by, for example, isolation and examination of serum samples from the chimeric animal, e.g., to assess function of the engrafted human hepatocytes, and/or to detect a pathogen in the animal's serum, e.g., to detect the presence of HCV or other microbial pathogen). The human hepatocytes can also be examined histologically to determine the effect of the patient sample.
The invention can also be adapted to provide for diagnosis and rationale therapy designed on an individualized basis. For example, human hepatocytes obtained by biopsy of a patient (e.g., percutaneous needle biopsy) can be used to produce the chimeric murine host. This chimeric murine host can then be used to evaluate the hepatotrophic pathogen infecting the patient, assess the pathogen's susceptibility to therapeutic agents, and to assess the potential toxicity of the patient's hepatocytes to such therapy. Thus the invention can be designed to facilitate tailoring of therapies most effective against an individual's specific hepatotrophic pathogen complement (e.g., against one or more infecting hepatotrophic pathogens).
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
To generate an Alb-uPA transgenic mouse tolerant to human tissue grafts, mice heterozygous for the transgene (strain TgN(AlblPlau)144Bri (The Jackson Laboratory)) were crossed with animals from a C.B-17/SCID-beige lineage (rain C.B-17/GbmsTac-scid-bgN7 (Taconic Farms), homozygous). Through a series of backcrosses, the SCID-beige trait was bred to homozygosity as confirmed by quantification of total serum IgG using a sandwich ELISA technique to detect mouse IgG according to methods well known in the art. Quantification of IgG was calculated from a standard curve prepared on each plate using a mouse IgG standard (Cappel). “Leakiness” of the SCID-beige trait was defined as >1% of normal serum IgG (Bosma et al. Ann. Rev. Immun. 9:323 (1991)); animals with serum IgG levels above this cutoff were euthanised. At each step, animals carrying the Alb-uPA transgene were identified by PCR analysis of genomic DNA extracted from tail biopsies, using two 18-mer primers that amplify a 151 bp product from the 3′ UTR of the transgene construct (Jackson Laboratories technical support). The transgene was maintained in the heterozygous state as the homozygous trait is associated with a high perinatal mortality rate secondary to bleeding complications and liver failure (Heckel et al. Cell 62:447 (1990)). Animals were housed in virus/antigen-free conditions, and were cared for in accordance with the guidelines established by the Canadian Council on Animal Care (1993). All animal experiments describe Herein were performed with approval from the University of Alberta Animal Welfare Committee.
Human hepatocytes for transplantation were obtained with approval from the University of Alberta Faculty of Medicine Research Ethics Board. Segments of human liver tissue (15-20 cm3) obtained at laparotomy were perfused with ice-cold Ca/Mg-free PBS containing 0.5 mM Na2EDTA. Prominent perfusing vessels were cannulated and the tissue was perfused for 30 minutes with recirculating carrier solution (35 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2, 50 mM HEPES, pH 7.6) containing 0.38 mg/mL Liberase CI collagenase (Boeringer-Mannheim) (Ryan et al. Surgery 113:48 (1993); Seglen et al. Meth. Cell Biol. 13:29 (1976)). Hepatocytes were filtered through 100 μm stainless steel mesh, purified by density-gradient centrifugation (Percoll, density 1.04 g/mL; Sigma) at 400 g for 5 minutes, and washed twice in ice-cold HBSS prior to suspension in Belzer-University of Wisconsin solution (DuPont) at 0° C. for short-term storage prior to transplantation. Cell counts and viability were confirmed by trypan blue exclusion prior to transplantation; final viability was routinely >80%.
Animals homozygous for the SCID trait and heterozygous for the Alb-uPA transgene were crossed, and 7 day-old progeny were transplanted with 1×106 freshly isolated viable human hepatocytes. Transplantation was accomplished by intrasplenic injection. Intrasplenically injected hepatocytes rapidly translocate to the liver via the portal venous system and engraft into the parenchyma surrounding terminal portal venules (Ponder et al. Proc. Natl. Acad. Sci. USA 88:1217 (1991); Gupta et al. Transplantation 50:472 (1990)). Since the mortality associated with intrasplenic injection is minimal, the spleen was selected as the optimal site for implantation. Accordingly, offspring (5-14 days old) were anesthetized with Halothane/O2, and a small left flank incision was made. Under operating magnification, 1×106 viable hepatocytes were injected into the inferior splenic pole with a 27 g butterfly injection set (Becton-Dickinson), and a single sterile titanium clip was placed across the injection site for hemostasis. The spleen was returned to the abdomen, and the flank incision was closed in two layers.
Since the production of albumin is an exclusive property of hepatocytes (Clement et al, Hepatology 4:373 (1984); Gunsalas et al. Nature Medicine 3:48 (1997)), detection of human albumin (HA) in serum samples by selective immunoprecipitation and Western blotting was employed as an indicator of graft cell function. Recipient mice were initially sampled by jugular venous puncture at four weeks post-transplant, and at weekly intervals thereafter. Aliquots of mouse serum (20 μl) were incubated with an anti-human albumin monoclonal antibody (Clone HSA-9; Sigma), and antigen-antibody complexes were precipitated with protein G-agarose (Boehringer-Mannheim). Imnunoprecipitates were heated for 5 minutes at 98° C. in SDS buffer containing 0.2 M dithiothreitol, separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Western blots were prepared in standard fashion (Coligan et al. Current Protocols in Immunology (Wiley, N.Y., 1997), vol. 2, chap. 8.10.7) using a second anti-human albumin monoclonal antibody (Clone HSA- 11; Sigma) conjugated to biotin as the primary. A streptavidin-HRP conjugate (Pierce) was employed as the secondary, and chemiluminescent reagents (Pierce) were used for signal detection.
A strong HA signal was demonstrated in the serum of 4/7 transplanted littermates, indicating the presence of significant numbers of functional human hepatocytes; subsequent genotype analysis revealed that all HA-positive animals carried the Alb-uPA transgene, whereas all the animals negative for HA were also negative for the transgene. Clear HA bands were detected as early as two weeks post-transplant, with an increase in intensity over the 4-6 week timepoints, suggesting vigorous expansion of the primary cell grafts (FIG. 1). These findings indicated that the microenvironment within the Alb-uPA liver was sufficient to stimulate human hepatocytes to begin rapid proliferation, and that there was the potential to support the establishment of long-term human grafts.
To confirm proliferation and estimate the extent of replacement of murine parenchyma with human-derived cells, cryosections of recipient livers were obtained at various times after transplantation and immunostained with a monoclonal antibody specific for human MHC Class I. Segments of mouse liver were placed in OCT compound and snap-frozen in liquid nitrogen. Cryosections were fixed in acetone and embedded in paraffin; immunohistochemistry was performed as previously described (Korbutt et al. J Clin Invest 97:2119 (1996)). A murine monoclonal antibody specific for human MHC Class I was expressed and purified from the BB7.7 cell line (ATCC), conjugated to biotin and used as the primary antibody. An avidin/peroxidase complex (Vector; Burlingame, Calif.) was used as a secondary, with peroxide/diaminobenzidine employed as the chromagen.
The results of these experiments are shown in FIGS. 2-5. In animals carrying the transgene, clusters of cells staining positive for human MHC (darkly stained cells) were scattered uniformly throughout the host liver at two weeks post-transplant, comprising an estimated 2-3% of all hepatocytes (FIGS. 2 (control) and 3 (transplanted)). At four weeks the percentage of positive-staining cells had increased, covering from 20 to 60% of the total surface area of individual sections (FIG. 4). The interface between human and mouse cells was distinct, with cords of human cells extending into the surrounding murine parenchyma (FIG. 5). Individual human cells maintained a normal appearance and developed sinusoidal architecture, although portal triad structures were notably absent from the regenerating nodules. This latter observation was not unexpected, since human-derived nodules are the result of clonal expansion of individual hepatocytes (Sandgren et al. Cell 68:245 (1991)). These nodules would contain no bile duct or endothelial precursor cells; such structures would be host-derived and therefore marginalized around proliferating human tissue.
This example demonstrates successful transplantation of the immunocompromised, Alb-uPA mice with human hepatocytes.
To determine the long-term outcome of initial successful engraftment and proliferation, a second litter of 8 animals was transplanted in similar fashion. The hepatocytes available for use at the time of this experiment were obtained from a patient who was a chronic carrier of hepatitis B virus. The patient exhibited both a positive serum HBsAg levels and negative serum HBV DNA, indicating a chronic carrier state without active viral replication (Davis, South. Med. J. 90:866 (1997)).
Two randomly selected animals were sacrificed at 4 weeks for histologic analysis, and the remaining 6 animals were followed at weekly intervals. Serum samples were subjected to Western blot as described above, and the HA bands from Western blots quantified using image analysis software and band densitometry (Umax Astra 1200S scanner and VistaScan DA v.1.2.2 imaging software (UMAX Copr, Fremont, Calif.). Quantification of HA peaks was performed using NIH Image 1.60/fat software (National Institute of Health), and normalized to a 50 ng HA standard present on each blot.
Again, initial graft proliferation was seen only in the 4 animals which carried the transgene. In these animals, HA signals remained near maximal to 8 weeks at which point two distinct patterns of graft function emerged (FIG. 6; Mouse 3, open square; Mouse 4, closed triangle; Mouse 5, open circle; Mouse 6, closed circle).
In three animals graft function began to slowly decline, with extinction of the HA signal at 10, 15 or 16 weeks. In contrast, the fourth transgenic animal (mouse no. 6) showed maximal HA production at all measured timepoints (FIGS. 6 and 7), indicating stable engraftment of human hepatocytes. Sustained graft function repeatedly occurred in approximately 25% of animals carrying the transgene. The proliferative signal for the transplanted hepatocytes is likely dependent on overall expression of the transgene, and is reduced as host-derived hepatocytes spontaneously delete the transgene.
In order to assess whether the transplanted mice supported the HBV infection of the HBV-infected, transplanted cells, serum samples from all transplanted mice were screened for hepatitis B surface antigen (HBsAg) production by sandwich ELISA. Aliquots of serum (20 μl) were tested for presence of HBsAg using a sandwich ELISA kit (Heprofile HbsAg; ADI Diagnostics) with plate analysis performed using a Dynatech MRX microplate spectrophotometer (Dynex). Both positive and negative human serum controls, as well as negative murine serum controls were included in assays.
The results are summarized in Table 1. Negative human and mouse serum controls range from 0.04-0.05 absorbance units; positive human controls range from 0.30-0.40 absorbance units.
TABLE 1 |
Analysis of serum markers of hepatitis B infection following transplantation of mice |
with HBV-infected human hepatocytes. |
HA | |||
Alb-uPA | Expression | HBsAg Level Post-Transplant* |
| Genotype | Pattern | 6 |
8 |
10 |
12 wk | 16 wk | |
1 | − | Absent | ND | 0.04 | 0.04 | 0.04 | |
2 | − | Absent | 0.04 | 0.03 | ND | 0.02 | ND |
3 | + | Transient | 0.04 | 0.03 | 0.08 | 0.05 | |
4 | + | Transient | 0.12 | 0.04 | 0.07 | 0.04 | |
5 | + | Transient | 0.04 | 0.03 | ND | 0.04 | |
6 | + | Persistent | 0.13 | 0.13† | 3.18† | 3.78† | 3.44† |
Key: HA — human albumin; ND — not done; *HBsAg levels expressed as absorbance units. †Samples positive for HBV DNA by PCR analysis. |
As expected, control (Alb-uPA negative, nos. 1-2) mice had undetectable HBsAg levels and the three transgenic animals with transient graft function showed only sporadic minimal increases during weeks 6-12. However, the transgenic mouse with the pattern of sustained graft function (mouse no. 6) demonstrated clearly elevated levels at all time points measured, with an abrupt increase after 8 weeks to persist well within the range of HBsAg levels in actively infected human controls. The abrupt increase was suggestive of restoration of active viral replication.
To confirm active replication samples of serum taken from this animal at 8, 10, 12 and 16 weeks were analyzed by PCR for the presence of HBV DNA. DNA isolated from 12.5 μl of mouse serum were subjected to PCR using HBV-specific primers and amplification conditions previously described (Tipples et al. Hepatology 24:714 (1996)). All analyses were performed in blinded fashion. All four serum samples were strongly positive for the presence of viral DNA (data not shown). This result was of special interest in that despite not actively replicating within its human donor, the virus was reactivated within the immunodeficient murine host. This reactivation may have been the result of inadequate antiviral immunity, similar to what is observed in chronic HBV carriers given pharmacologic immunosuppression after organ transplantation (Terrault et al. Gut 40:568 (1997)).
This example thus demonstrates that human hepatocytes transplanted into chimeric, transgenic mice can support HBV viral replication.
The success above in production of a chimeric animal that supports HBV replication in the chimeric mouse supports the use of the animal as a model of HBV. However, the vast differences between HBV and HCV discussed above (Background) meant that there could be no reasonable expectation that the animal model would be susceptible to HCV infection through a normal route of infection (e.g., intravenous transmission) or that the chimeric liver could support an active HCV infection, particularly in view of the failure of others to develop HCV animal models and the rarity of cell systems for HCV. The comparative success with HBV animals models and the repeated failures of others with HCV animal models indicate that one can not simply extrapolate from HBV to HCV. Thus, an attempt was made to establish a primary HCV infection in mice with chimeric livers using virally-infected human serum.
Seven littermates were transplanted at 7 days of age with human hepatocytes isolated from a patient serologically-negative for both HCV and HBV infection. After confirming initial graft function in 5/7 animals at 6 weeks post-transplant, all mice were inoculated intravenously with 0.25 mL of human serum obtained from an unrelated HCV-positive donor. The HCV-positive status of the human serum donor was confirmed positive for HCV RNA by PCR, with viral titers of 1×107 copies per ml serum. Thus, each mouse was inoculated with approximately 2.5×106 viral particles. Serum samples taken from all seven mice at 11, 12 and 13 weeks post-transplant (5, 6 and 7 weeks post-infection) were analyzed for the presence of HCV RNA by RT-PCR analysis using the Cobras Amplicon system (Roche Diagnostics), according to the manufacturer's instructions. Two nontransplanted mice served as mock-infected controls.
Of the five animals with good initial engraftment, four showed the pattern of transient graft function and again one animal demonstrated HA levels at maximal intensity over all measured timepoints. All three samples taken from the animal with sustained human chimerism were strongly positive for HCV RNA, and persistently positive at weekly intervals to 36 weeks. RT-PCR analysis was uniformly negative for animals negative for the Alb-uPA transgene or that only transiently expressed the HA marker for the transgene.. As 6 animals were negative for HCV RNA, the possibility of the positive RT-PCR signals in the seventh animal originating from residual virus rather than from the inoculum is remote. This example supports the conclusion that this animal had developed and at 23 weeks post-transplantation and 20-weeks post-infection, is propagating an active HCV infection at 1.2×105-1.8×105 virion/ml serum.
This series of experiments establishes the capacity of the SCID-beige/Alb-uPA transgenic mouse to generate and sustain a chimeric human liver for prolonged and perhaps indefinite periods of time after transplantation of human hepatocytes. These chimeric organs can be infected de novo with HCV-positive human serum, and can support long-term replication (e.g., for a period of weeks or months as opposed to a few days) of human-specific hepatotrophic viruses at levels that can be equated to clinical levels in humans. HCV viral particles can be detected in serum, blood, or other blood-derived fraction by standard techniques, which techniques can be automated to facilitate more rapid screening. For example, the samples from the HCV-infection host can be diluted with known noninfected serum (e.g., about two to four fold dilution), to provide a sample volume adequate for use in an automated machine, and provide signal strengths in the assays indistinguishable from random human samples.
Long-term replication of HCV in the model of the invention (e.g., for a period longer than about 4 weeks, generally longer than about 12 weeks, e.g., about 3 months to 6 months or more) allows for the use of the model in the testing of drugs over extended periods of time, which period may be necessary for adequate drug development. For example, the effect of administration of interferon-α, an anti-HCV therapy, is generally only detectable in humans after about 12 weeks of therapy. An animal model that sustained viral replication for only a few days or weeks and/or exhibited inconsistent viral production, it would be difficult or impossible to determine if changes in viral titers were due to a candidate therapeutic or to normal fluctuations in titer inherent in the animal model. The present invention provides a model that avoids this problem.
In summary, to the best of the inventors' knowledge, this is the first report of a non-primate animal model that is susceptible to HCV infection by a normal route of infection. The model is clinically relevant (e.g., can be infected by a normal route of infection, and supports persistent HCV infection similar to that observed in humans), is cost-effective and relatively easy to produce, and will allow investigators to directly explore strategies for inhibiting viral replication in vivo.
The above experiments of Example 3 were repeated in 18 mice. The mouse name (used as an internal reference), gender, number of copies of the Alb-uPA transgene, identify of parents and date of birth (DOB) for each animal is provided in Table 2. Mice were transplanted with either fresh (fresh) or fresh frozen (cryo) human hepatocytes at ages ranging from 7 days to 13 days. The HA signal was detected by Western blot at 5 weeks to identify those animals that were successfully engrafted. The animals were subsequently infected with HCV as described above. RT-PCR was used to detect the presence of HCV in samples form each animal as described above. The results are summarized in Table 2. Where RT-PCR was performed quantitatively to determine the number of virions per ml of serum, the data is provided. Table legend: M=male, F=female; notations under “Parents” indicates “names” of parents used as internal references; DOB=date of birth of animal; Txplt=Date of Transplant; # cells=number of cells (in millions), with f=fresh cells and c=cryopreserved cells; Txplt Age=age of animal at transplant (in days); 5 w Alb results from albumin test at 5 weeks); HCV=date of infection with HCV; RT-PCR=date of test for presence of HCV with (N)=negative and (P)=positive; and Rpt wstrn=date and results of confirmatory Western blot for presence of HCV. “Quantitative titres” indicates both the titer and the date(s) the titre was measured. Homo=homozygous for the uPA gene; Hetero=heterozygous for the uPA gene; 0=no copies of the uPA gene. Asterisks denote mice positive for HCV.
Txplt | Quantitative | |||||||||||
Mouse | Sex | uPA | Parents | DOB | Txplt | # cells | Age | 5 w Alb | HCV | RT-PCR | titres | Rpt wstrn |
A6MRA* | M | Homo | 30-Mar | 6-Apr | 1 M f | 7 d. | +++ | 18-May | Jun 23, | 1.81 X 10EA - | |
|
30 (P) | |
|||||||||||
Jul 7, 15, | 1.78 X 10E3 - | |||||||||||
21 (P) | Aug 11 | |||||||||||
Sep 1 (P) | 1.43 X 10E3 - | |||||||||||
Aug 18 | ||||||||||||
Nov 4 (N) | 1.22 X 10E4 - | |||||||||||
Sep 21 | ||||||||||||
Jan 27 (N) | ||||||||||||
Feb 26 (N) | Jul29 < 10EA | |||||||||||
Aug23 < 10E4 | ||||||||||||
Oct13 < 10E3 | ||||||||||||
A27MLP | M | Hetero | 23-Apr | 27-Apr | .5 M f | 4 d. | +++ | 15-Jun | July 7, 15, | |||
22 (N) | ||||||||||||
Aug 11(N) | ||||||||||||
18-Aug | Sept 15, | |||||||||||
22(N) | ||||||||||||
Oct21, | Jan 17 ++ | |||||||||||
Nov4(N) | ||||||||||||
3-Dec | Dec 22 (N) | Feb 11 ++ | ||||||||||
A27MLM | M | Hetero | 23-Apr | 27-Apr | .5 M f | 4 d. | +++ | 15-Jun | July 7, 15, | Jan 17 | ||
22(N) | +++ | |||||||||||
Aug11(N) | ||||||||||||
18-Aug | Sept15, | |||||||||||
22 (N) | ||||||||||||
Oct21, | ||||||||||||
Nov4(N) | ||||||||||||
3-Dec | Dec22(N) | |||||||||||
A27MRA | M | Hetero | 23-Apr | 27-Apr | .5 M f | 4 d. | +++ | 15-Jun | July7, 15, | Jan 17 − | ||
22(N) | ||||||||||||
Aug11(N) | ||||||||||||
18-Aug | Sept15, | |||||||||||
22(N) | ||||||||||||
Oct21, | ||||||||||||
Nov4(N) | ||||||||||||
3-Dec | Dec 22 (N) | |||||||||||
Oct 12F* | F | Homo | 71F X 56M | 5-Oct | 12-Oct | 1 M f | 7 d | +++ | 3-Dec | Dec 22 (P) | Jan 6 1.35 X | Feb 2 |
10E6 | +++ | |||||||||||
Jan 14 (P) | ||||||||||||
Feb 11 (P) | ||||||||||||
71Nov9FLA | F | Hetero | 71F X 56M | 30-Oct | 9-Nov | 1 M f | 10 d | +++ | 5-Jan | Jan 27 (N) | Dec 9 | |
+++ | ||||||||||||
Feb 11 (P) | ||||||||||||
+++ | ||||||||||||
71Nov9FLM | F | Hetero | 71F X 56M | 30-Oct | 9-Nov | 1 M f | 10 d | +++ | 5-Jan | Jan 27 (N) | Dec 9 | |
+++ | ||||||||||||
Feb 11 | ||||||||||||
+++ | ||||||||||||
71Nov9M* | M | Homo | 71F X 56M | 30-Oct | 9-Nov | 1 M f | 10 d | +++ | 5-Jan | Jan 27 (P) | Feb 11 | |
+++ | ||||||||||||
Feb 11 (P) | ||||||||||||
Sep2M | M | Hetero | LP X LP | 20-Aug | 2-Sep | 1 M c | 13 d | +++ | 14-Oct | Nov 3 (N) | Jan 17 − | |
Nov 24 (N) | ||||||||||||
Sep2FRP | F | Hetero | LP X LP | 20-Aug | 2-Sep | 1 M c | 13 d | +++ | 14-Oct | Nov 3 (N) | Jan 17 − | |
Nov 24 (N) | ||||||||||||
Aug31FLM | F | 0 | LM X LM | 19-Aug | 31-Aug | 1 M f | 12 d | ++ | 14-Oct | Nov 3 (N) | Dec 8 − | |
Nov5MRM | M | 0 | Aug 24F | 26-Oct | 5-Nov | 1 M f | 10 d | ++ | 13-Dec | Jan 6 (N) | Feb 2 ? + | |
Nov5MLM | M | 0 | Aug 24F | 26-Oct | 5-Nov | 1 M f | 10 d | + | 13-Dec | Jan 6 (N) | Feb 2 − | |
Aug31Msolo | M | Hetero | LA X LA | 19-Aug | 31-Aug | 1 M f | 12 d | +++ | 1-Nov | Nov 24 (N) | Dec 8 − | |
Oct5AMRM | M | Hetero | LA X LA | 22-Sep | 5-Oct | 0.58 M | 13 d | +++ | 3-Dec | Dec 22 (N) | Jan 6 OD | Jan 7 +++ |
f | too low | |||||||||||
Jan 14 (N) | Feb 11 ++ | |||||||||||
Nov16FRA* | F | Homo | LA X LA | 6-Nov | 16-Nov | 0.2 M c | 10 d | +++ | 5-Jan | Jan 27 (P) | Feb 11 | |
+++ | ||||||||||||
Feb 11 (P) | ||||||||||||
Nov16FRM | F | Hetero | LA X LA | 6-Nov | 16-Nov | 0.2 M c | 10 d | ++ | 5-Jan | Jan 27 (N) | Feb 11 − | |
Oct5BFLM | F | Hetero | 88F X 40M | 24-Sep | 5-Oct | 0.58 M | 11 d | +++ | 3-Dec | Dec 22 (N) | Jan 6 OD | Feb 11 − |
f | too low | |||||||||||
Jan 14 (N) | ||||||||||||
Dec17MLM | M | Homo | 71FX56M | 13-Dec | 17-Dec | ?1M | 4 d | +++ | 24-Feb | |||
Nov16MLMRM | M | Hetero | LA X LA | 6-Nov | 16-Nov | 0.2 M c | 10 d | ++ | 24-Feb | |||
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.
Claims (18)
1. A chimeric transgenic mouse host infected with human hepatitis C virus (HCV) comprising:
an immunodeficient, transgenic mouse whose genome comprises a polynucleotide encoding a urokinase-type plasminogen activator polypeptide, wherein the polynucleotide is operably linked to a promoter such that the polypeptide is expressed in host mouse liver cells, and wherein the host is homozygous for the polynucleotide; and
a chimeric liver comprising human hepatocytes engrafted into mouse host liver;
wherein inoculation of the chimeric mouse host with human HCV results in HCV infection of the mouse host.
2. The chimeric mouse host of claim 1 , wherein human hepatocytes constitute at least about 20% of hepatocytes in the chimeric liver.
3. The chimeric mouse host of claim 1 , wherein the human hepatocytes are functional for at least about 8 weeks.
4. The chimeric mouse host of claim 1 , wherein the host is infected with human hepatitis C virus following hepatocyte engraftment.
5. The chimeric mouse host of claim 4 , wherein the infected host is characterized by production of at least about 105 viral particles/mL of serum.
6. The chimeric mouse host of claim 4 , wherein the infected host maintains consistently detectable HCV infection for a period of at least 8 weeks.
7. The chimeric mouse host of claim 1 , wherein the promoter is a mouse albumin promoter.
8. The chimeric mouse host of claim 1 , wherein the host immunodeficiency is caused by a scid mutation.
9. The chimeric mouse host of claim 8 , wherein the host further comprises a beige mutation.
10. A method of producing a chimeric transgenic mouse host infected with human hepatitis C virus (HCV), the method comprising:
implanting human hepatocytes into an immunodeficient, transgenic mouse host whose genome comprises a polynucleotide encoding a urokinase-type plasminogen activator polypeptide, wherein the polynucleotide is operably linked to a promoter, such that the polypeptide is expressed in host mouse liver cells and wherein the host is homozygous for the polynucleotide; and
inoculating the host with human HCV;
wherein a chimeric transgenic mouse host comprising a human-mouse chimeric liver and having a human HCV infection is produced.
11. A chimeric mouse host produced by the method of claim 10 .
12. A method for screening candidate agents for activity against a hepatotrophic pathogen, the method comprising the steps of:
administering a candidate agent to the chimeric mouse host of claim 1 ; and
analyzing the effect of the candidate agent upon HCV infection;
wherein a decrease in infectious load of the human HCV relative to an untreated chimeric transgenic mouse host or relative to infectious load in the chimeric transgenic mouse host prior to candidate agent administration is indicative of anti-HCV activity of the agent.
13. The method of claim 12 , wherein the candidate agent is administered prior to infection with human HCV.
14. A method of culturing human hepatitis C virus (HCV), the method comprising:
administering human HCV to the chimeric transgenic mouse host of claim 1 ; and
isolating human HCV from the infected host following human HCV replication in the host.
15. The chimeric transgenic mouse of claim 1 , wherein the promoter is an albumin promoter.
16. The chimeric mouse of claim 1 , wherein the human hepatocytes do not contain detectable HCV prior to engraftment in the mouse liver.
17. A chimeric transgenic mouse infected with human hepatitis C virus (HCV) comprising:
an immunodeficient mouse whose genome comprises a polynucleotide encoding a urokinase-type plasminogen activator polypeptide, wherein the polynucleotide is operably linked to a promoter such that the polypeptide is expressed in mouse liver cells and wherein the host is homozygous for the transgene; and
a chimeric liver comprising human hepatocytes engrafted into mouse liver;
wherein inoculation of the chimeric mouse with human HCV results in HCV infection of the mouse such that the infected mouse is characterized by production of at least about 104 viral copies/mL of serum.
18. The chimeric transgenic mouse of claim 17 , wherein the infected mouse is characterized by production of at least about 105 viral copies/mL of serum.
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/528,120 US6509514B1 (en) | 2000-03-17 | 2000-03-17 | Chimeric animal model susceptible to human hepatitis C virus infection |
DK01914893.1T DK1265480T3 (en) | 2000-03-17 | 2001-03-16 | Chimeric experimental animal susceptible to human hepatitis C virus infection |
JP2001566336A JP4059672B2 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis C virus infection |
DE60142281T DE60142281D1 (en) | 2000-03-17 | 2001-03-16 | TITIS C VIRUS IS INFICIBLE |
AT01914893T ATE469547T1 (en) | 2000-03-17 | 2001-03-16 | CHIMERIC ANIMAL MODEL INFECTABLE WITH THE HUMAN HEPATITIS C VIRUS |
CA2402117A CA2402117C (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
AU2001242163A AU2001242163B2 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
IL15162101A IL151621A0 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
PCT/CA2001/000350 WO2001067854A1 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
NZ521119A NZ521119A (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis C virus infection |
EP01914893A EP1265480B1 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
KR1020027012249A KR100656795B1 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
ES01914893T ES2346636T3 (en) | 2000-03-17 | 2001-03-16 | CHEMERIC ANIMAL MODEL SUSCEPTIBLE TO VIRUS INFECTION OF HUMAN HEPATITIS C. |
AU4216301A AU4216301A (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
IL151621A IL151621A (en) | 2000-03-17 | 2002-09-04 | Chimeric animal model susceptible to human hepatitis c virus infection |
US10/243,087 US7161057B2 (en) | 2000-03-17 | 2002-09-12 | Animal model having a chimeric human liver |
US11/517,941 US7498479B2 (en) | 2000-03-17 | 2006-09-07 | Animal model having a chimeric human liver |
JP2007191518A JP4436389B2 (en) | 2000-03-17 | 2007-07-24 | Chimeric animal model susceptible to human hepatitis C virus infection |
US12/333,002 US7781642B2 (en) | 2000-03-17 | 2008-12-11 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US12/840,188 US8212106B2 (en) | 2000-03-17 | 2010-07-20 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US13/484,073 US8445745B2 (en) | 2000-03-17 | 2012-05-30 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/528,120 US6509514B1 (en) | 2000-03-17 | 2000-03-17 | Chimeric animal model susceptible to human hepatitis C virus infection |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2001/000350 Continuation-In-Part WO2001067854A1 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
US10/243,087 Continuation-In-Part US7161057B2 (en) | 2000-03-17 | 2002-09-12 | Animal model having a chimeric human liver |
Publications (1)
Publication Number | Publication Date |
---|---|
US6509514B1 true US6509514B1 (en) | 2003-01-21 |
Family
ID=24104337
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/528,120 Expired - Lifetime US6509514B1 (en) | 2000-03-17 | 2000-03-17 | Chimeric animal model susceptible to human hepatitis C virus infection |
US10/243,087 Expired - Lifetime US7161057B2 (en) | 2000-03-17 | 2002-09-12 | Animal model having a chimeric human liver |
US11/517,941 Expired - Fee Related US7498479B2 (en) | 2000-03-17 | 2006-09-07 | Animal model having a chimeric human liver |
US12/333,002 Expired - Fee Related US7781642B2 (en) | 2000-03-17 | 2008-12-11 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US12/840,188 Expired - Fee Related US8212106B2 (en) | 2000-03-17 | 2010-07-20 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US13/484,073 Expired - Fee Related US8445745B2 (en) | 2000-03-17 | 2012-05-30 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/243,087 Expired - Lifetime US7161057B2 (en) | 2000-03-17 | 2002-09-12 | Animal model having a chimeric human liver |
US11/517,941 Expired - Fee Related US7498479B2 (en) | 2000-03-17 | 2006-09-07 | Animal model having a chimeric human liver |
US12/333,002 Expired - Fee Related US7781642B2 (en) | 2000-03-17 | 2008-12-11 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US12/840,188 Expired - Fee Related US8212106B2 (en) | 2000-03-17 | 2010-07-20 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US13/484,073 Expired - Fee Related US8445745B2 (en) | 2000-03-17 | 2012-05-30 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
Country Status (13)
Country | Link |
---|---|
US (6) | US6509514B1 (en) |
EP (1) | EP1265480B1 (en) |
JP (2) | JP4059672B2 (en) |
KR (1) | KR100656795B1 (en) |
AT (1) | ATE469547T1 (en) |
AU (2) | AU2001242163B2 (en) |
CA (1) | CA2402117C (en) |
DE (1) | DE60142281D1 (en) |
DK (1) | DK1265480T3 (en) |
ES (1) | ES2346636T3 (en) |
IL (2) | IL151621A0 (en) |
NZ (1) | NZ521119A (en) |
WO (1) | WO2001067854A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050005312A1 (en) * | 1999-11-02 | 2005-01-06 | Wu George Y. | Propagation of human hepatocytes in non-human animals |
EP1552740A1 (en) * | 2004-01-09 | 2005-07-13 | Institut Pasteur | Chimeric murine model comprising human hepatocytes - use for screening compounds |
US20050255591A1 (en) * | 2002-03-25 | 2005-11-17 | Chise Mukaidani | Method of proliferating human hepatocytes and method for obtaining human hepatocytes |
WO2006021896A2 (en) | 2004-08-27 | 2006-03-02 | Tripep Ab | Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics |
US20060156420A1 (en) * | 2004-08-20 | 2006-07-13 | Kneteman Norman M | Malarial animal model having a chimeric human liver |
US20070107069A1 (en) * | 2000-03-17 | 2007-05-10 | Kneteman Norman M | Animal model having a chimeric human liver |
US20080199847A1 (en) * | 2004-08-20 | 2008-08-21 | Daiichi Pure Chemicals Co., Ltd. | Method for Predicting the Metabolism of Drug in Human Liver and Liver Function |
US20090047655A1 (en) * | 2004-11-16 | 2009-02-19 | Chise Mukaidani | Method Of Screening Candidate Drug |
US20100081965A1 (en) * | 2008-10-01 | 2010-04-01 | John Mugan | Needle biopsy device |
US20100121218A1 (en) * | 2008-10-01 | 2010-05-13 | Boston Endoscopic Engineering Corporation | Device for needle biopsy with integrated needle protection |
US20100325747A1 (en) * | 2007-06-05 | 2010-12-23 | Markus Grompe | Method of expanding human hepatocytes in vivo |
US20110041192A1 (en) * | 2008-02-21 | 2011-02-17 | Lishan Su | Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis |
WO2011133284A1 (en) | 2010-04-22 | 2011-10-27 | Oregon Health & Science University | Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof |
WO2012048170A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Institute Of Technology | Humanized animals via tissue engineering and uses therefor |
WO2013032918A1 (en) | 2011-08-26 | 2013-03-07 | Yecuris Corporation | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof |
CN103088106A (en) * | 2013-01-25 | 2013-05-08 | 中国水产科学研究院淡水渔业研究中心 | Method for screening fish liver protection medicaments by using fish primary hepatocyte damage model |
US20150128298A1 (en) * | 2012-04-27 | 2015-05-07 | Tokyo Metropolitan Institute Of Medical Science | Urokinase-type plasminogen activator transgenic mouse |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9420769B2 (en) | 2011-10-13 | 2016-08-23 | Phoenixbio Co., Ltd. | Chimeric non-human animal carrying human hepatocyte |
US9566315B2 (en) | 2013-11-01 | 2017-02-14 | Oregon Health & Science University | Normalization of the enterohepatic circulation in animals with a chimeric humanized liver |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
WO2018152120A1 (en) | 2017-02-14 | 2018-08-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
US11266766B2 (en) | 2015-10-08 | 2022-03-08 | Massachusetts Institute Of Technology | Situ expansion of engineered devices for regeneration |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US11324858B2 (en) | 2012-07-10 | 2022-05-10 | The Trustees Of The University Of Pennsylvania | Biomaterials for enhanced implant-host integration |
US11716974B2 (en) | 2016-06-27 | 2023-08-08 | Baylor College Of Medicine | Human liver chimeric mouse with deficient P450 oxidoreductase |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002028174A1 (en) * | 2000-10-03 | 2004-02-12 | 財団法人 東京都医学研究機構 | Hepatitis C virus infection method |
US20030096316A1 (en) * | 2001-11-21 | 2003-05-22 | Ingmar Wester | Use of apolipoprotein B as a single marker for evaluation of the risk or cardiovascular disease |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
EP2614709A1 (en) * | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
CN101550425B (en) * | 2008-03-31 | 2011-03-30 | 北京大学 | Method for manufacturing adjustable liver injury animal model and special carriers thereof |
JP5710097B2 (en) * | 2008-07-10 | 2015-04-30 | 株式会社バイオマーカーサイエンス | Evaluation method of arteriosclerosis improvement / prevention effect, screening method of substance, and use as marker |
CN101748123B (en) * | 2008-11-27 | 2012-11-07 | 北京大学 | Manufacturing method of adjustable liver damage animal model and special DNA fragment thereof |
KR101742329B1 (en) * | 2009-01-16 | 2017-05-31 | 고에끼 자이단 호우징 짓껭 도부쯔 쥬오 겡뀨쇼 | Mouse having human hepatocytes transplanted therein |
WO2013047720A1 (en) | 2011-09-30 | 2013-04-04 | 公立大学法人横浜市立大学 | Method for inducing hepatocellular variation, and production method for chimeric non-human animal having humanized liver |
SG11201402112RA (en) * | 2011-12-06 | 2014-09-26 | Massachusetts Inst Technology | Use of humanized mice to determine toxicity |
JP5871412B2 (en) * | 2012-03-27 | 2016-03-01 | 株式会社トランスジェニック | Humanized mouse |
US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
CN106047870B (en) * | 2016-06-16 | 2019-01-08 | 中国医学科学院医学生物学研究所 | Tree shrew MHC-DRB1*1101 gene order and its application |
EP3687288A4 (en) * | 2017-09-25 | 2021-06-30 | National University of Singapore | A chimeric animal comprising stably transplanted bat cells |
KR102362814B1 (en) | 2020-06-04 | 2022-02-15 | 한국생명공학연구원 | Animal model for transplanting human hepatocytes and a method for screening anti-viral agent by using the animal model |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0438053A1 (en) | 1990-01-15 | 1991-07-24 | Yeda Research And Development Company Limited | Durable engraftment and development of human hematopoietic lineages in normal mammals |
WO1993007165A1 (en) | 1991-10-09 | 1993-04-15 | The Scripps Research Institute | Lipoprotein assays using antibodies to a pan native epitope and recombinant antigens |
WO1994002601A1 (en) | 1992-07-24 | 1994-02-03 | The Trustees Of The University Of Pennsylvania | Non-native liver generation in an animal with impaired native liver function by cell implantation |
WO1994027556A2 (en) | 1993-05-17 | 1994-12-08 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
WO1996018419A1 (en) | 1994-12-14 | 1996-06-20 | University Of Washington | Recombinant vectors for permanent reconstitution of liver and treatment of hepatitis c |
US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5804160A (en) | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
WO1998042824A2 (en) | 1997-03-20 | 1998-10-01 | Cellfactors Plc | Methods for selecting cells and their uses |
US5849987A (en) | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US5858328A (en) | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
WO1999016307A1 (en) | 1997-09-26 | 1999-04-08 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis c virus |
WO1999046598A1 (en) | 1998-03-10 | 1999-09-16 | The Regents Of The University Of California | Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding |
US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
US5994617A (en) * | 1988-09-19 | 1999-11-30 | Hsc Research Development Corporation | Engraftment of immune-deficient mice with human cells |
WO2000017338A1 (en) | 1998-09-18 | 2000-03-30 | Albert Einstein College Of Medicine Of Yeshiva University | Upa/rag-2 mouse with mammalian repopulating hepatocytes for infection by hepadnaviruses |
WO2001032009A1 (en) | 1999-11-02 | 2001-05-10 | The University Of Connecticut | Propagation of human hepatocytes in non-human animals |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476996A (en) * | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
WO1996039810A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Human hepatocellular tissue in chimeric immunocompromised animals |
AU715822B2 (en) * | 1996-03-15 | 2000-02-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Tissue adhesive suitable for spray application |
US6864402B1 (en) * | 1998-09-18 | 2005-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Chronic hepatitis virus infection and clonal hepatocellular carcinoma in mouse repopulated livers |
US6249089B1 (en) * | 1998-10-09 | 2001-06-19 | Frederick Bruwer | Intelligent electrical device comprising microchip |
WO2001005955A2 (en) * | 1999-07-14 | 2001-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
US6509514B1 (en) | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
-
2000
- 2000-03-17 US US09/528,120 patent/US6509514B1/en not_active Expired - Lifetime
-
2001
- 2001-03-16 ES ES01914893T patent/ES2346636T3/en not_active Expired - Lifetime
- 2001-03-16 NZ NZ521119A patent/NZ521119A/en not_active IP Right Cessation
- 2001-03-16 IL IL15162101A patent/IL151621A0/en active IP Right Grant
- 2001-03-16 AU AU2001242163A patent/AU2001242163B2/en not_active Ceased
- 2001-03-16 CA CA2402117A patent/CA2402117C/en not_active Expired - Fee Related
- 2001-03-16 EP EP01914893A patent/EP1265480B1/en not_active Expired - Lifetime
- 2001-03-16 DK DK01914893.1T patent/DK1265480T3/en active
- 2001-03-16 WO PCT/CA2001/000350 patent/WO2001067854A1/en active IP Right Grant
- 2001-03-16 DE DE60142281T patent/DE60142281D1/en not_active Expired - Lifetime
- 2001-03-16 KR KR1020027012249A patent/KR100656795B1/en active IP Right Grant
- 2001-03-16 JP JP2001566336A patent/JP4059672B2/en not_active Expired - Fee Related
- 2001-03-16 AU AU4216301A patent/AU4216301A/en active Pending
- 2001-03-16 AT AT01914893T patent/ATE469547T1/en active
-
2002
- 2002-09-04 IL IL151621A patent/IL151621A/en not_active IP Right Cessation
- 2002-09-12 US US10/243,087 patent/US7161057B2/en not_active Expired - Lifetime
-
2006
- 2006-09-07 US US11/517,941 patent/US7498479B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 JP JP2007191518A patent/JP4436389B2/en not_active Expired - Fee Related
-
2008
- 2008-12-11 US US12/333,002 patent/US7781642B2/en not_active Expired - Fee Related
-
2010
- 2010-07-20 US US12/840,188 patent/US8212106B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 US US13/484,073 patent/US8445745B2/en not_active Expired - Fee Related
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994617A (en) * | 1988-09-19 | 1999-11-30 | Hsc Research Development Corporation | Engraftment of immune-deficient mice with human cells |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
EP0438053A1 (en) | 1990-01-15 | 1991-07-24 | Yeda Research And Development Company Limited | Durable engraftment and development of human hematopoietic lineages in normal mammals |
US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5709843A (en) | 1990-01-15 | 1998-01-20 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoietic deficient immune systems |
US5858328A (en) | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5804160A (en) | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
WO1993007165A1 (en) | 1991-10-09 | 1993-04-15 | The Scripps Research Institute | Lipoprotein assays using antibodies to a pan native epitope and recombinant antigens |
US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5849987A (en) | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
WO1994002601A1 (en) | 1992-07-24 | 1994-02-03 | The Trustees Of The University Of Pennsylvania | Non-native liver generation in an animal with impaired native liver function by cell implantation |
WO1994027556A2 (en) | 1993-05-17 | 1994-12-08 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
WO1996018419A1 (en) | 1994-12-14 | 1996-06-20 | University Of Washington | Recombinant vectors for permanent reconstitution of liver and treatment of hepatitis c |
US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
WO1998042824A2 (en) | 1997-03-20 | 1998-10-01 | Cellfactors Plc | Methods for selecting cells and their uses |
US6034297A (en) * | 1997-09-26 | 2000-03-07 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis C virus |
WO1999016307A1 (en) | 1997-09-26 | 1999-04-08 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis c virus |
WO1999046598A1 (en) | 1998-03-10 | 1999-09-16 | The Regents Of The University Of California | Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding |
WO2000017338A1 (en) | 1998-09-18 | 2000-03-30 | Albert Einstein College Of Medicine Of Yeshiva University | Upa/rag-2 mouse with mammalian repopulating hepatocytes for infection by hepadnaviruses |
WO2001032009A1 (en) | 1999-11-02 | 2001-05-10 | The University Of Connecticut | Propagation of human hepatocytes in non-human animals |
Non-Patent Citations (35)
Title |
---|
A.P. Dhillon, et al., "Pathology of Hepatitis C Virus Infection", Histopathology 26:297-309 (1995). |
CA Kappel et al., Current Biology, "Regulating gene expression in transgenic animals," 1992, 3: 548-553.* * |
Camille Sureau, "In Vitro Culture Systems for Hepatitis B and Delta Viruses", Arch. Virol. 8:3-14 (1993). |
Chantal Fournier, et al, In Vitro Infection of Adult Normal Human Hepatocytes in Primary Culture by Hepatitis C Virus, J. Gen. Virol. 79,(Pt 10); 2367-2374 (1998). |
Crabb (2001) "Hard-Won Advances Spark Excitement About Hepatitis C" Science, vol. 294: 506-507. |
Craig N. Shapiro, MD, "Occupational Risk of Infection with Hepatitis B and Hepatitis C Virus", Surgical Clinics North Amer. 75(6):1047-1056 (1995). |
Dandri et al. (2001) "Repopulation of Mouse Liver With Human Hepatocytes and In Vivo Infection With Hepatitis B Virus" Hepatology, 33(4) 981-988. |
David W. Oldach, "Murine Model for Hepatitis C Virus Investigations", University of Maryland Balt Prof School (1998). |
Eithan Galun, et al., "Hepatitis C Virus Viremia in SCID->BNX Mouse Chimera", J Infect Dis. 172:25-30 (1995). |
Eithan Galun, et al., "Hepatitis C Virus Viremia in SCID→BNX Mouse Chimera", J Infect Dis. 172:25-30 (1995). |
Eric P. Sandgren, et al., "Complete Hepatic Regeneration After Somatic Deletion of an Albumin-Plasminogen Activator Transgene", Cell 66:245-256 (1990). |
Hervé Lerat, et al., "Hepatitis C Virus Transgenic Mice as Model for HCV Associated Liver Disease", Hepatology 28 (4Pt2); 498A (1998). |
J. Nicolet, et al. Caractérisation de la Régénération Hépatique Chez la Souris Transgénique Albumine-Urokinase, Chirurgie 123(1):47-53, (Feb. 1998). |
Janice L. Heckel, et al., "Neonatal Bleeding In Transgenic Mice Expressing Urokinase-Type Plasminogen Activator", Cell 62:447-456 (1990). |
Jean-Pierre Bronowicki, et al. "Hepatitis C Virus Persistence in Human Hematopoietic Cells Injected Into SCID Mice" Hepatology 28:211-8 (1998). |
Joerg Petersen, et al., "Liver Repopulation with Xenogenic Hepatocytes in B and T Cell-deficient Mice Leads to Chronic Hepadnavirus Infection and Clonal Growth of Hepatocellular Carcinoma", Proc. Nat'l. Acad. Sci. USA 95:310-315 (1998). |
Jonathan A. Rhim, et al., "Complete Reconstitution of Mouse Liver with Xenogeneic Hepatocytes", Proc. Nat'l. Acad. Sci. USA 92:4942-4946 (1995). |
Jonathan A. Rhim, et al., "Replacement of Diseased Mouse Liver by Hepatic Cell Transplantation", Science 263:1149-1152 (1994). |
Lieber et al. (1995) "A Modified Urokinase Plasminogen Activator Induces Liver Regeneration Without Bleeding" Human Gene Therapy, vol. 6: 1029-1037. |
Lieber et al. (1995) "Adenovirus-mediated Urokinase Gene Transfer Induces Liver Regeneration and Allows for Efficient Retrovirus Transduction of Hepatocytes in vivo" Proc. National Academy of Science, Genetics, vol. 92(20): 6210-6214. |
LJ Mullins et al., Transgenesis in Nnmurine Species, "Perspectives Series:Molecular Medicine in Genetically Engineered Animals," Supp.1996, vol. 98, No. 11, pp. S37-S40.* * |
L-M Houdebine, Journal of Biotechnology, "Production of pharmaceutical proteins from transgenic animals," 1994, 34:269-287.* * |
M Houghton, Fields Virology, "Hepatitis C Viruses," 1996, 3rd Ed., Chap. 32, pp. 1035-1036.* * |
Mary Ann Sells, et al., "Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected With Cloned Hepatitis B Virus DNA", Proc. Nat'l. Acad. Sci. USA 84:1005-1009 (1987). |
McBurney et al. (1994) "Murine PGK-1 Promoter Drives Widespread But Not Uniform Expression in Transgenic Mice" Developmental Dynamics, vol. 200(4): 278-298. |
Mercer et al. (2001) "Hepatitis C Virus replication in Mice With Chimeric Human Livers" Nature Medicine, vol. 7(8): 1-7. |
Nelson Fausto (2001) "A Mouse Model For Hepatitis C Virus Infection?" Nature Medicine, vol. 7(8) 890-891. |
Pietro Lampertico, et al., "Development and Application of an In Vitro Model for Screening Anit-hepatitis B Virus Therapeutics", Hepatology 13:422-6 (1991). |
RJ Wall, Theriogenology, "Transgenic Livestock: Progress and Prospects for the Future," 1996, 45:57-68.* * |
T. Ito, et al., "Cultivation of Hepatitis C Virus in Primary Hepatocyte Culture from Patients with Chronic Hepatitis C Results in Release of High Titre Infectious Virus", J. Gen Virol. 77:1043 (1995). |
Toth, L.R. et al. (1996) "Two Distinct apolipoprotein B alleles in mice generated by a single "in-out' targeting", Gene: An International Journal on Genes and Genomes, G.B.,Elsevier Science, Publishers, Barking, vol. 178 (1):161-168. |
Vrancken-Peeters et al. (1997) "Expansion of Donor Hepatocytes After Recombinant Adenovirus-Induced Liver Regeneration in Mice" Hepatology, vol. 25(4): 884-888. |
Weglarz et al. (2000) "Hepatocyte Transplantation into Diseased Mouse Liver", American Journal of Pathology, vol. 157(6):1963-1974. |
Youhua Liu, et al., "Molecular Cloning and Characterization of cDNA Encoding Mouse Hepatocyte Growth Factor", Biochim et Biophys Acta 1216:299-303 (1993). |
Zhi-Chun Xie, et al., "Transmission of Hepatitis C Virus Infection to Tree Shrews", Virology 244:513-520 (1998). |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050005312A1 (en) * | 1999-11-02 | 2005-01-06 | Wu George Y. | Propagation of human hepatocytes in non-human animals |
US20110167507A1 (en) * | 2000-03-17 | 2011-07-07 | Kneteman Norman M | Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection |
US8445745B2 (en) | 2000-03-17 | 2013-05-21 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US20090151012A1 (en) * | 2000-03-17 | 2009-06-11 | Kneteman Norman M | Animal Model Having a Chimeric Human Liver and Susceptible to Human Hepatitis C Virus Infection |
US7781642B2 (en) | 2000-03-17 | 2010-08-24 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US20070107069A1 (en) * | 2000-03-17 | 2007-05-10 | Kneteman Norman M | Animal model having a chimeric human liver |
US8212106B2 (en) * | 2000-03-17 | 2012-07-03 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection |
US7498479B2 (en) | 2000-03-17 | 2009-03-03 | Kmt Hepatech, Inc. | Animal model having a chimeric human liver |
US20050255591A1 (en) * | 2002-03-25 | 2005-11-17 | Chise Mukaidani | Method of proliferating human hepatocytes and method for obtaining human hepatocytes |
US7560279B2 (en) * | 2002-03-25 | 2009-07-14 | Hiroshima Industrial Promotion Organization | Method of proliferating human hepatocytes and method for obtaining human hepatocytes |
WO2005067709A2 (en) * | 2004-01-09 | 2005-07-28 | Institut Pasteur | Chimeric murine model comprising human hepatocytes user for screening compounds |
WO2005067709A3 (en) * | 2004-01-09 | 2005-11-24 | Pasteur Institut | Chimeric murine model comprising human hepatocytes user for screening compounds |
EP1552740A1 (en) * | 2004-01-09 | 2005-07-13 | Institut Pasteur | Chimeric murine model comprising human hepatocytes - use for screening compounds |
US20080199847A1 (en) * | 2004-08-20 | 2008-08-21 | Daiichi Pure Chemicals Co., Ltd. | Method for Predicting the Metabolism of Drug in Human Liver and Liver Function |
US7273963B2 (en) | 2004-08-20 | 2007-09-25 | Kmt Hepatech, Inc. | Malarial animal model having a chimeric human liver |
WO2006023593A3 (en) * | 2004-08-20 | 2006-10-19 | Kmt Hepatech Inc | Malarial animal model having a chimeric human liver |
US20060156420A1 (en) * | 2004-08-20 | 2006-07-13 | Kneteman Norman M | Malarial animal model having a chimeric human liver |
WO2006021896A2 (en) | 2004-08-27 | 2006-03-02 | Tripep Ab | Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics |
US20090047655A1 (en) * | 2004-11-16 | 2009-02-19 | Chise Mukaidani | Method Of Screening Candidate Drug |
US20100325747A1 (en) * | 2007-06-05 | 2010-12-23 | Markus Grompe | Method of expanding human hepatocytes in vivo |
US8569573B2 (en) | 2007-06-05 | 2013-10-29 | Oregon Health & Science University | Method of expanding human hepatocytes in vivo |
US9173383B2 (en) * | 2008-02-21 | 2015-11-03 | The University Of North Carolina At Chapel Hill | Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis |
US20110041192A1 (en) * | 2008-02-21 | 2011-02-17 | Lishan Su | Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis |
US9913630B2 (en) | 2008-10-01 | 2018-03-13 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US20100081965A1 (en) * | 2008-10-01 | 2010-04-01 | John Mugan | Needle biopsy device |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US11039816B2 (en) | 2008-10-01 | 2021-06-22 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US10888689B2 (en) | 2008-10-01 | 2021-01-12 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US10076316B2 (en) | 2008-10-01 | 2018-09-18 | Covidien Lp | Needle biopsy device |
US20100121218A1 (en) * | 2008-10-01 | 2010-05-13 | Boston Endoscopic Engineering Corporation | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
WO2011133284A1 (en) | 2010-04-22 | 2011-10-27 | Oregon Health & Science University | Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof |
US10004826B2 (en) | 2010-10-06 | 2018-06-26 | Massachusetts Institute Of Technology | Implantable human liver tissue constructs and uses thereof |
WO2012048170A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Institute Of Technology | Humanized animals via tissue engineering and uses therefor |
EP3578042A1 (en) | 2011-08-26 | 2019-12-11 | Yecuris Corporation | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof |
WO2013032918A1 (en) | 2011-08-26 | 2013-03-07 | Yecuris Corporation | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof |
US9420769B2 (en) | 2011-10-13 | 2016-08-23 | Phoenixbio Co., Ltd. | Chimeric non-human animal carrying human hepatocyte |
US11051496B2 (en) | 2012-04-27 | 2021-07-06 | Tokyo Metropolitan Institute Of Medical Science | Urokinase-type plasminogen activator transgenic mouse |
US20150128298A1 (en) * | 2012-04-27 | 2015-05-07 | Tokyo Metropolitan Institute Of Medical Science | Urokinase-type plasminogen activator transgenic mouse |
US9955675B2 (en) * | 2012-04-27 | 2018-05-01 | Tokyo Metropolitan Institute Of Medical Science | Urokinase-type plasminogen activator transgenic mouse |
US11324858B2 (en) | 2012-07-10 | 2022-05-10 | The Trustees Of The University Of Pennsylvania | Biomaterials for enhanced implant-host integration |
US11617817B2 (en) | 2012-07-10 | 2023-04-04 | The Trustees Of The University Of Pennsylvania | Biomaterials for enhanced implant-host integration |
CN103088106A (en) * | 2013-01-25 | 2013-05-08 | 中国水产科学研究院淡水渔业研究中心 | Method for screening fish liver protection medicaments by using fish primary hepatocyte damage model |
US9566315B2 (en) | 2013-11-01 | 2017-02-14 | Oregon Health & Science University | Normalization of the enterohepatic circulation in animals with a chimeric humanized liver |
US11266766B2 (en) | 2015-10-08 | 2022-03-08 | Massachusetts Institute Of Technology | Situ expansion of engineered devices for regeneration |
US11338065B2 (en) | 2015-10-08 | 2022-05-24 | Massachusetts Institute Of Technology | In situ expansion of engineered devices for regeneration |
US11716974B2 (en) | 2016-06-27 | 2023-08-08 | Baylor College Of Medicine | Human liver chimeric mouse with deficient P450 oxidoreductase |
WO2018152120A1 (en) | 2017-02-14 | 2018-08-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
Also Published As
Publication number | Publication date |
---|---|
US7498479B2 (en) | 2009-03-03 |
AU2001242163B2 (en) | 2005-06-23 |
NZ521119A (en) | 2004-03-26 |
US20030115616A1 (en) | 2003-06-19 |
US20110167507A1 (en) | 2011-07-07 |
DE60142281D1 (en) | 2010-07-15 |
ATE469547T1 (en) | 2010-06-15 |
JP4059672B2 (en) | 2008-03-12 |
ES2346636T3 (en) | 2010-10-19 |
US7161057B2 (en) | 2007-01-09 |
AU4216301A (en) | 2001-09-24 |
US20090151012A1 (en) | 2009-06-11 |
US8445745B2 (en) | 2013-05-21 |
US8212106B2 (en) | 2012-07-03 |
US20070107069A1 (en) | 2007-05-10 |
CA2402117A1 (en) | 2001-09-20 |
JP2003526348A (en) | 2003-09-09 |
DK1265480T3 (en) | 2010-09-20 |
WO2001067854A1 (en) | 2001-09-20 |
JP4436389B2 (en) | 2010-03-24 |
CA2402117C (en) | 2012-01-17 |
KR20030027883A (en) | 2003-04-07 |
IL151621A0 (en) | 2003-04-10 |
US7781642B2 (en) | 2010-08-24 |
KR100656795B1 (en) | 2006-12-12 |
EP1265480A1 (en) | 2002-12-18 |
IL151621A (en) | 2006-06-11 |
JP2008022853A (en) | 2008-02-07 |
US20120309032A1 (en) | 2012-12-06 |
EP1265480B1 (en) | 2010-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6509514B1 (en) | Chimeric animal model susceptible to human hepatitis C virus infection | |
AU2001242163A1 (en) | Chimeric animal model susceptible to human hepatitis C virus infection | |
JP6573924B2 (en) | Fumaryl acetoacetate hydrolase (FAH) deficient and immunodeficient rats and their use | |
US6525242B1 (en) | Propagation of human hepatocytes in non-human mammals | |
US6995299B2 (en) | Propagation of human hepatocytes in non-human animals | |
CN109136273B (en) | Method for preparing immunodeficient rat and application thereof | |
WO2020122178A1 (en) | Non-human vertebrate transplanted with human hepatocytes and method for producing same | |
JP2008044898A (en) | Hemophilia b curative agent and method for producing the same | |
AU2002329766A1 (en) | Propagation of human hepatoblastoma cell in non-human animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KMT HEPATECH, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNETEMAN, NORMAN M.;TYRRELL, D. LORNE;MERCER, DAVID E.;REEL/FRAME:013215/0721 Effective date: 20021030 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |